[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 11012
1. Bortlik M, Vitkova I, Papezova M, Kohoutova M, Novotny A, Adamec S, Chalupna P, Lukas M: Deficiency of Adenomatous Polyposis Coli protein in sporadic colorectal adenomas and its associations with clinical phenotype and histology. World J Gastroenterol; 2006 Jun 28;12(24):3901-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deficiency of Adenomatous Polyposis Coli protein in sporadic colorectal adenomas and its associations with clinical phenotype and histology.
  • AIM: To evaluate the frequency of the loss of the Adenomatous Polyposis Coli (APC) protein and to compare the APC status with the characteristics of colorectal adenomas.
  • METHODS: Immunohistochemical analysis of the APC protein was performed on 118 adenomas and the results were compared with parameters of malignant potential, location of adenomas, macroscopic appearance and age of the patients.
  • RESULTS: A complete loss of the APC protein was found in 28 (24%) adenomas, while 90 (76%) were APC positive.
  • The mean size of adenomas was 13.5 +/- 14.2 mm (95% CI 10.5-16.5) in APC-positive, and 13.8 +/- 15.5 mm (95% CI 7.8-19.8) in APC-negative adenomas (P = 0.364).
  • Statistical analysis revealed no difference between APC-positive and negative adenomas as to the histological type (P = 0.327) and grade of dysplasia (P = 0.494).
  • We found that even advanced adenomas did not differ in their APC status from the non-advanced tumors (P = 0.414).
  • Finally, no difference was found when the location (P = 0.157), macroscopic appearance (P = 0.571) and age of patients (P = 0.438) were analysed and compared between both APC positive and negative adenomas.
  • CONCLUSION: Most adenomas expressed full-length APC protein, suggesting that protein expression is not a reliable marker for assessment of APC gene mutation.
  • Complete loss of APC protein did not influence morphology, location, or appearance of adenomas, nor was it affected by the patient's age.
  • [MeSH-major] Adenoma / genetics. Adenoma / pathology. Adenomatous Polyposis Coli Protein / genetics. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. DNA Mutational Analysis. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Middle Aged. Mutation. Phenotype. Severity of Illness Index

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2000 Nov;21(11):1935-40 [11062151.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4366-71 [10969779.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):599-611 [11522744.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9433-8 [12093899.001]
  • [Cites] Int J Colorectal Dis. 2003 May;18(3):203-9 [12673484.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1757-63 [14578176.001]
  • [Cites] Mol Cancer. 2003 Dec 12;2:41 [14672538.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2846-50 [8385345.001]
  • [Cites] Hum Mutat. 1993;2(6):425-34 [8111410.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3011-20 [8187091.001]
  • [Cites] Nat Genet. 1994 Mar;6(3):217-9 [8012377.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3553-6 [8012980.001]
  • [Cites] J Pathol. 1997 Apr;181(4):426-33 [9196441.001]
  • [Cites] J Pathol. 1998 Aug;185(4):360-5 [9828834.001]
  • [Cites] Nat Med. 1999 Sep;5(9):1071-5 [10470088.001]
  • [Cites] J Cell Sci. 2004 Dec 15;117(Pt 26):6339-53 [15561772.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):37-43 [15375009.001]
  • [Cites] Pediatr Res. 2005 Jan;57(1):4-9; discussion 1-3 [15557107.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2280-7 [16181381.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):721-33 [11257105.001]
  • (PMID = 16804979.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC4087942
  •  go-up   go-down


2. Rishi A, Sharma MC, Sarkar C, Jain D, Singh M, Mahapatra AK, Mehta VS, Das TK: A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience. Neurol India; 2010 May-Jun;58(3):418-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience.
  • BACKGROUND: Non-functioning pituitary adenomas (NFPA) are characterized by the lack of clinical syndrome as compared to functioning adenomas (FA) but not all functioning adenomas have clinical effects.
  • RESULTS: Of the 151 pituitary adenomas diagnosed during a period of one and half years, 77 (51%) were NFPA with a male predominance.
  • On the basis of immunohistochemistry, NFPA were classified into three subtypes; gonadotroph adenomas, silent adenomas, and null cell adenomas.
  • Gonadotroph adenomas were the commonest subtype.
  • [MeSH-major] Adenoma / metabolism. Adenoma / pathology. Pituitary Neoplasms / metabolism. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644271.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Luteinizing Hormone, beta Subunit; 9002-60-2 / Adrenocorticotropic Hormone; 9002-68-0 / Follicle Stimulating Hormone; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


3. Rubio CA: Do stem cells participate in cell turnover in duodenal adenomas? A preliminary study on Paneth cells. Anticancer Res; 2008 May-Jun;28(3A):1571-3
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do stem cells participate in cell turnover in duodenal adenomas? A preliminary study on Paneth cells.
  • MATERIALS AND METHODS: The spatial position of Paneth cells within the profile of histological sections was investigated with hematoxilin and eosin (H&E) in 6 duodenal adenomas; 2 of them were also immonostained with lysozyme, an enzyme present in Paneth cells.
  • In the two immunostained adenomas, the numbers of lysozyme-expressing cells/high power field were 15 and 42, respectively.
  • The lysozyme-stained cells were present at all levels in the adenomas, including the luminal epithelial layer.
  • CONCLUSION: In duodenal adenomas, not all Paneth cells detected by lysozyme immunostain are apparent in H&E-stained sections, suggesting that lysozyme immunostain also detects Paneth cells precursors.
  • Since mature Paneth cells and their precursors are positioned underneath the stem cells, it is conceivable that the Paneth cells that had reached the luminal aspect of the adenomas, were preceded by stem cells.
  • This possibility would imply that in duodenal adenomas, the stem cells would be subjected to the same laws that orchestrate the turnover of epithelial duodenal cells, including Paneth cells and their precursors.
  • [MeSH-major] Adenoma / pathology. Duodenal Neoplasms / pathology. Neoplastic Stem Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630513.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 3.2.1.17 / Muramidase
  •  go-up   go-down


Advertisement
4. Kamiyama T, Fukukura Y, Yoneyama T, Takumi K, Nakajo M: Distinguishing adrenal adenomas from nonadenomas: combined use of diagnostic parameters of unenhanced and short 5-minute dynamic enhanced CT protocol. Radiology; 2009 Feb;250(2):474-81
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing adrenal adenomas from nonadenomas: combined use of diagnostic parameters of unenhanced and short 5-minute dynamic enhanced CT protocol.
  • PURPOSE: To retrospectively examine the diagnostic values of individual parameters obtained from unenhanced and 35-second and 5-minute contrast material-enhanced (enhanced) computed tomography (CT) in distinguishing adenomas, particularly lipid-poor adenomas, from nonadenomas and to determine the best diagnostic method by using these parameters.
  • The study population consisted of 61 patients (20 men and 41 women; mean age, 58 years) with 68 adrenal masses (53 adenomas and 15 nonadenomas).
  • Adenomas were classified as 30 lipid-rich (<or=10 HU) and 23 lipid-poor (>10 HU) adenomas by using unenhanced attenuation.
  • The diagnostic parameters were tumor size, unenhanced attenuation, 35-second and 5-minute enhanced attenuation, wash-in and washout attenuation, percentage enhancement washout ratio (PEW), and relative PEW (RPEW).
  • The sensitivity, specificity, and accuracy for diagnosing adenomas were calculated by using a threshold level of each parameter determined by the least sum of false-positive and false-negative cases and a combination of the threshold levels with 100% specificity.
  • RESULTS: The best results were obtained by using a combination of the threshold levels with 100% (15 of 15) specificity (presence of at least one of the following criteria for diagnosing adenomas: unenhanced attenuation of <or=19 HU, 5-minute attenuation of <or=50 HU, PEW of >or=45%, and RPEW of >or=31%).
  • Sensitivity was 94% (50 of 53) or 87% (20 of 23) and accuracy was 96% (65 of 68) or 92% (35 of 38) for diagnosing total adrenal adenomas or lipid-poor adenomas, respectively.
  • [MeSH-major] Adrenal Gland Neoplasms / radiography. Adrenocortical Adenoma / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037020.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


5. Moreno CS, Evans CO, Zhan X, Okor M, Desiderio DM, Oyesiku NM: Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res; 2005 Nov 15;65(22):10214-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses.
  • Pituitary adenomas comprise 10% of intracranial tumors and occur in about 20% of the population.
  • To further elucidate the molecular changes that contribute to the development of these tumors and reclassify them according to the molecular basis, we investigated 11 nonfunctional pituitary adenomas and eight normal pituitary glands, using 33 oligonucleotide GeneChip microarrays.
  • We validated microarray results with the reverse transcription real-time quantitative PCR, using a larger number of nonfunctional adenomas.
  • We also used proteomic analysis to examine protein expression in these nonfunctional adenomas.
  • We observed changes in expression of SFRP1, TLE2, PITX2, NOTCH3, and DLK1, suggesting that the developmental Wnt and Notch pathways are activated and important for the progression of nonfunctional pituitary adenomas.
  • We further analyzed gene expression profiles of all nonfunctional pituitary subtypes to each other and identified genes that were affected uniquely in each subtype.
  • These results show distinct gene and protein expression patterns in adenomas, provide new insight into the pathogenesis and molecular classification of nonfunctional pituitary adenomas, and suggest that therapeutic targeting of the Notch pathway could be effective for these tumors.
  • [MeSH-major] Adenoma / classification. Pituitary Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288009.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K22-CA96560; United States / NINDS NIH HHS / NS / NS 42843; United States / NCI NIH HHS / CA / R01-CA106826; United States / NCRR NIH HHS / RR / RR-10522; United States / NCRR NIH HHS / RR / RR-14593
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


6. Ma CY, Lu YC, Shi JX, Ren CC, Zhu JD, Gu JR: [Experimental study of dually targeting gene therapy system for pituitary adenomas]. Zhonghua Yi Xue Za Zhi; 2005 Jan 26;85(4):262-6
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experimental study of dually targeting gene therapy system for pituitary adenomas].
  • OBJECTIVE: To construct a dually targeting gene therapy system for pituitary adenomas and investigate its effect.
  • Human growth hormone-secreting pituitary adenoma cells of the GH3 line, human myeloma cells of the U-2OS line, and human oophoroma cells of the HO8910PM line were cultured and transfected with PBS or GE7 packaged pcDNA3.1/HisA-TK or pcDNA3.1/HisA-hGHp-TK.
  • GH3 cells were injected subcutaneously into the right axilla of 200 SD nude rats loaded with human pituitary adenoma.
  • Three weeks after the rats were randomly divided into 5 equal groups: PBS group in which PBS was injected into the tumor and GCV was injected peritoneally; GE7 group in which GE7-polylysine and HA20-polylysine were injected into the tumor and GCV was injected peritoneally; without TK group in which GE7-packaged pcDNA3.1/His A-hGHp was injected into the tumor and GCV was injected peritoneally; without GCV group in which GE7-packaged pcDNA3.1/His A-hGHp-TK was injected into the tumor and PBS was injected peritoneally; and treatment group in which GE7-packaged pcDNA3.1/His A-hGHp-TK was injected into the tumor and GCV was injected peritoneally.
  • On the days 3, 7, 14, and 21 eight rats from each group were killed to measure the volume of tumor.
  • RESULTS: A dually targeting gene therapy system for pituitary adenoma was composed successfully.
  • Three days after the beginning of treatment the tumor volume of different groups of rats increased at different degrees and the tumor was smallest in the treatment group in comparison with the other groups (all P < 0.05).
  • Seven days after the beginning of treatment the tumor volume of the treatment group significantly decreased and the tumors of the other groups still increased (all P < 0.001).
  • CONCLUSION: GE7 system-mediated hGHp controlled gene therapy system is hopeful to be the targeted therapeutic strategy for pituitary adenomas.
  • [MeSH-major] Adenoma / therapy. Genetic Therapy. Pituitary Neoplasms / therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Ganciclovir / pharmacology. Ganciclovir / therapeutic use. Gene Transfer Techniques. Herpesvirus 1, Human / genetics. Male. Neoplasm Transplantation. Random Allocation. Rats. Rats, Sprague-Dawley. Thymidine Kinase / genetics. Transfection

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854489.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


7. Halvarsson B, Lindblom A, Johansson L, Lagerstedt K, Nilbert M: Loss of mismatch repair protein immunostaining in colorectal adenomas from patients with hereditary nonpolyposis colorectal cancer. Mod Pathol; 2005 Aug;18(8):1095-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of mismatch repair protein immunostaining in colorectal adenomas from patients with hereditary nonpolyposis colorectal cancer.
  • Colorectal adenomas occur at younger age, at increased frequency and have a greater tendency for malignant transformation in patients with hereditary nonpolyposis colorectal cancer (HNPCC).
  • We performed immunostaining for the mismatch repair proteins MLH1, PMS2, MSH2 and MSH6 in 35 colorectal adenomas from 26 patients with HNPCC and identified loss of immunostaining in 23/35 (0.66) adenomas.
  • Loss of mismatch repair protein immunostaining was particularly frequent in large (>5 mm) (14/16) and proximally located (13/15) adenomas, whereas the gene mutated--MLH1 or MSH2--and the type of mutation did not seem to affect the results.
  • We conclude that loss of mismatch repair protein immunostaining is detected at a lower rate in adenomas than in carcinomas associated with HNPCC.
  • Adenomatous tissue can thus be used for immunostaining of mismatch repair proteins in clinical investigations of HNPCC, but whereas loss of immunostaining may pinpoint the gene affected and thereby guide mutation analysis, retained staining cannot exclude that the adenoma developed as part of the syndrome due to reduced sensitivity.
  • However, the analysis has a greater chance of being informative if large and proximally located adenomas are selected.
  • [MeSH-major] Adenoma / pathology. Colorectal Neoplasms / pathology. Colorectal Neoplasms, Hereditary Nonpolyposis / pathology. DNA Repair
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenosine Triphosphatases / analysis. Adult. Aged. Base Pair Mismatch. Carrier Proteins. DNA Repair Enzymes / analysis. DNA-Binding Proteins / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. MutS Homolog 2 Protein. Neoplasm Proteins / analysis. Nuclear Proteins / analysis. Proto-Oncogene Proteins / analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15731775.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / PMS2 protein, human; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


8. Chanson P, Brochier S: Non-functioning pituitary adenomas. J Endocrinol Invest; 2005;28(11 Suppl International):93-9
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-functioning pituitary adenomas.
  • The vast majority (>80%) of clinically non-functioning pituitary adenomas (NFPAs) are gonadotroph-cell adenomas, as demonstrated by immunocytochemistry.
  • The strategy of observation only for patients with incidentally discovered pituitary adenomas may be appropriate, provided that the tumor is well-delimited, small, has no extension with risk of neurological or visual chiasm compression, and that a meticulous hormonal work-up has ruled out the possibility of a minimal hormonal hypersecretion.
  • Prolonged administration of GnRH antagonist in a small number of patients with a secreting gonadotroph cell adenoma has been reported to reduce supranormal gonadotropins levels but not to produce any change in tumoral size.
  • [MeSH-major] Adenoma. Pituitary Neoplasms

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625856.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 9002-62-4 / Prolactin; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  • [Number-of-references] 66
  •  go-up   go-down


9. Viacava P, Bocci G, Tonacchera M, Fanelli G, DeServi M, Agretti P, Berti E, Goletti O, Aretini P, Resta ML, Bevilacqua G, Naccarato AG: Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: a comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules. Thyroid; 2007 Mar;17(3):191-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: a comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules.
  • OBJECTIVE: To perform (i) an immunohistochemical investigation of cell proliferation, apoptosis, angiogenesis, and malignancy markers in 15 functioning and 15 nonfunctioning thyroid adenomas, and in normal adjacent tissue, and (ii) a genetic analysis of thyroid-stimulating hormone receptor (TSH-r), Gsalpha, and RAS mutations in the same group of adenomas, in order to describe their expression within tissues and to correlate them with the hormonal functioning.
  • Adenomas and normal adjacent tissues were evaluated by immunohistochemistry using the following antibodies: MIB-1 for proliferative activity, bcl-2 and mutant p53 for apoptosis control, vascular endothelial growth factor-A (VEGF-A) for angiogenic activity, and galectin-3 as a marker for malignancy.
  • Genetic analysis for TSH-r, Gsalpha, and H-, K-, and N-RAS mutations was performed on adenoma specimens.
  • MAIN OUTCOMES: Our results evidenced that a proportion of both functioning and nonfunctioning adenomas showed immunohistochemical phenotypes similar to normal adjacent tissue.
  • No differences were found between functioning and nonfunctioning thyroid adenomas with regard to the expression of markers associated to angiogenesis (VEGF-A, microvascular density) and apoptosis control (mutant p53, bcl-2).
  • All adenomas resulted negative for galectin-3 immunostaining.
  • MIB-1 was the only marker showing a substantial difference of expression between the two groups of adenomas.
  • TSH-r mutations were found in 12 out of 15 functioning adenomas, whereas the absence of Gsalpha and H-, K-, and N-RAS mutations was demonstrated in all adenomas.
  • CONCLUSIONS: Our data suggest that the differences between functioning and nonfunctioning thyroid adenomas are restricted to the genetic mutations of the TSH-r, to the hormonal status of tumors, and to the proliferative activity, not involving markers of apoptosis control and angiogenesis.
  • [MeSH-major] Adenoma / genetics. Adenoma / pathology. Apoptosis. Neovascularization, Pathologic. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology
  • [MeSH-minor] Antigens, CD34 / biosynthesis. Biomarkers, Tumor / metabolism. Cell Proliferation. Humans. Immunohistochemistry / methods. Proto-Oncogene Proteins c-bcl-2 / metabolism. Sequence Analysis, DNA. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17381350.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


10. Rex DK: Maximizing detection of adenomas and cancers during colonoscopy. Am J Gastroenterol; 2006 Dec;101(12):2866-77
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maximizing detection of adenomas and cancers during colonoscopy.
  • Some patients who undergo colonoscopy that appeared to have cleared the colorectum of neoplasia return within a short interval (1-3 yr) with colorectal cancer.
  • Although several a priori mechanisms could account for this occurrence, wide variation in detection rates of adenomas and cancer at colonoscopy suggests that suboptimal colonoscopic technique is a significant contributor.
  • In two randomized controlled trials, CE improved adenoma detection, but CE does not appear to provide substantially greater yields than those obtained by the more sensitive white-light colonoscopists.
  • Adenoma detection rates are an important measure of the quality of colonoscopy and should be reported to endoscopists in quality improvement programs in colonoscopy.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Colonoscopy / methods

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17227527.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 91
  •  go-up   go-down


11. Inan N, Arslan A, Akansel G, Anik Y, Balci NC, Demirci A: Dynamic contrast enhanced MRI in the differential diagnosis of adrenal adenomas and malignant adrenal masses. Eur J Radiol; 2008 Jan;65(1):154-62
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic contrast enhanced MRI in the differential diagnosis of adrenal adenomas and malignant adrenal masses.
  • OBJECTIVE: To evaluate the value of dynamic MR imaging in the differential diagnosis of adrenal adenomas and malignant tumors, especially in cases with atypical adenomas.
  • MATERIALS AND METHODS: Sixty-four masses (48 adenomas, 16 malignant tumors) were included in this prospective study.
  • RESULTS: Chemical shift MR imaging was able to differentiate 44 out of 48 adenomas (91.7%) from non-adenomas.
  • The 4 adenomas (8.3%) which could not be differentiated from non-adenomas by this technique did not exhibit signal loss on out-of-phase images.
  • With a cut-off value of 30, SI indices of adenomas had a sensitivity of 93.8%, specificity of 100% and a positive predictive value of 100%.
  • On visual evaluation of dynamic MR imaging, early phase contrast enhancement patterns were homogeneous in 75% and punctate in 20,83% of the adenomas; while patchy in 56.25% and peripheral in 25% of the malignant tumors.
  • On the late phase images 58.33% of the adenomas showed peripheral ring-shaped enhancement and 10.41% showed heterogeneous enhancement.
  • At the 25th second, the SIs and wash-in rates of the adenomas were significantly higher than those of the malignant masses (p=0.010).
  • Time-to-peak enhancement of the malignant masses was significantly longer than that of the adenomas.
  • CONCLUSION: Chemical shift MR has a high sensitivity and specificity in the differential diagnosis of adenomas and malignant adrenal masses.
  • However, taking into consideration only the atypical adenomas, chemical shift MRI is of no diagnostic value.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenocortical Adenoma / diagnosis. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466481.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


12. Misikangas M, Tanayama H, Rajakangas J, Lindén J, Pajari AM, Mutanen M: Inulin results in increased levels of beta-catenin and cyclin D1 as the adenomas increase in size from small to large in the Min/+ mouse. Br J Nutr; 2008 May;99(5):963-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inulin results in increased levels of beta-catenin and cyclin D1 as the adenomas increase in size from small to large in the Min/+ mouse.
  • The mechanism that drives the growth of some colonic adenomas towards malignancy, while permitting others to remain for decades in quiescence, remains unknown.
  • Diets can alter the growth rate of intestinal tumours but it is still unknown whether diets are able to alter the molecular biology of these adenomas in a way that predicts further outcome.
  • To address this issue we fed Min/+ mice with two diets known to lead to different adenoma outcomes: a high-fat control diet (n 15) or a high-fat inulin-enriched (10 % w/w) diet (n 13).
  • To study the effect of diet on cell signalling during adenoma growth, the adenomas of each Min/+ mouse were divided into three size-categories, and the levels of beta-catenin, E-cadherin, cyclin D1 and matrix metalloproteinase-9, which are known to be involved in colon tumorigenesis, were determined.
  • The growth-promoting inulin diet resulted in more large adenomas than the control feeding (P = 0.003) and doubled the total area of the adenomas (P = 0.008).
  • The inulin diet increased the expression of nuclear beta-catenin (P = 0.004) and its target cyclin D1 (P = 0.017) as the adenomas increased in size from small to large, indicating the presence of an accelerated cancerous process.
  • Neither phenomenon was seen in the control group during adenoma growth.
  • Our results suggest that in addition to the number, size, and growth rate of adenomatous polyps, the signalling pattern of the adenomas should also be considered when evaluating preventive dietary strategies.
  • [MeSH-major] Adenomatous Polyposis Coli / pathology. Cyclin D1 / metabolism. Diet. Inulin / pharmacology. beta Catenin / metabolism
  • [MeSH-minor] Animals. Cadherins / metabolism. Dietary Fats / administration & dosage. Disease Models, Animal. Disease Progression. Mice. Mice, Inbred C57BL. Neoplasm Proteins / metabolism. Signal Transduction / drug effects

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17977470.001).
  • [ISSN] 0007-1145
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / Dietary Fats; 0 / Neoplasm Proteins; 0 / beta Catenin; 136601-57-5 / Cyclin D1; 9005-80-5 / Inulin
  •  go-up   go-down


13. Occhi G, Albiger N, Berlucchi S, Gardiman M, Scanarini M, Scienza R, Fassina A, Mantero F, Scaroni C: Peroxisome proliferator-activated receptor gamma in the human pituitary gland: expression and splicing pattern in adenomas versus normal pituitary. J Neuroendocrinol; 2007 Jul;19(7):552-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peroxisome proliferator-activated receptor gamma in the human pituitary gland: expression and splicing pattern in adenomas versus normal pituitary.
  • Pituitary adenomas are slow-growing tumours arising within the pituitary gland.
  • If secreting, they give rise to well-known syndromes such as Cushing's disease or acromegaly; when hormonally inactive, they come to clinical attention often with local mass effects or pituitary deficiency.
  • Peroxisome proliferator-activated receptor gamma (PPARgamma), a nuclear hormone receptor with a key role in fat and glucose metabolism, but also involved in several neoplasia, has recently been detected in pituitary adenomas.
  • In the present study, we evaluated the occurrence and splicing profile of PPARgamma in 43 cases of pituitary adenoma of different subtypes and compared it to 12 normal pituitary glands.
  • By real-time polymerase chain reaction, PPARgamma was expressed as much in adrenocorticotrophic hormone (ACTH)-secreting and ACTH-silent adenomas as in controls, with a moderate underexpression in somatotrophinomas and prolactinomas and overexpression in 54% of nonfunctioning pituitary adenomas (NFPA).
  • Western blotting revealed similar expression levels in the different subgroups of pituitary adenomas and normal glands.
  • The intra- and intergroup differences observed in pituitary adenomas may represent new elements in the process of understanding the different clinical responses of Cushing's and Nelson patients to PPARgamma-ligand treatment.
  • Moreover, the higher level of PPARgamma expression detected in the NFPA subgroup may suggest its possible role as a molecular target in these pituitary adenomas, paving the way for investigations on the effectiveness of treatment with thiazolidinediones in such patients.
  • [MeSH-major] Adenoma / metabolism. PPAR gamma / metabolism. Pituitary Gland / metabolism. Pituitary Neoplasms / metabolism. RNA Splicing

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561883.001).
  • [ISSN] 0953-8194
  • [Journal-full-title] Journal of neuroendocrinology
  • [ISO-abbreviation] J. Neuroendocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / PPAR gamma; 0 / RNA, Messenger
  •  go-up   go-down


14. Sajko T, Gnjidić I, Talan-Hranilović J: [The importance of the team work in diagnosis of pituitary adenomas: the five-tier World Health Organization classification]. Lijec Vjesn; 2005 May-Jun;127(5-6):134-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The importance of the team work in diagnosis of pituitary adenomas: the five-tier World Health Organization classification].
  • [Transliterated title] Vaznost sveukupnog dijagnostickog pristupa u klasifikaciji adenoma hipofize: upute svjetske zdravstvene organizacije.
  • In the last ten years great changes occurred concerning the basic knowledge on pituitary adenomas.
  • Many different classifications of pituitary adenomas were proposed.
  • In 2000 World Health Organization accepted the five-tier classification of pituitary adenomas proposed by Kovacs and Horvath.
  • It is based on clinical and biochemical results, neuroradiological imaging, operative findings, pathohistological examination, immunocytochemistry and electron microscopy studies on more than 10 000 surgically treated pituitary adenomas.
  • Its importance is that it supplies the endocrinologist, neurosurgeon and oncologist with valuable information concerning the biological behavior, growth potential, treatment response and prognosis of pituitary adenomas.
  • Together with the novel biological techniques that provide the data on tumor's growth rate, aggressiveness and invasiveness, they ar necessary in establishing the correct diagnosis which will direct patient's future treatment.
  • [MeSH-minor] Adenoma / classification. Adenoma / diagnosis. Humans. World Health Organization

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16281475.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


15. Chen L, Liu Y, Hou Y, Kato Y, Sano H, Kanno T: Expression and structure of interleukin 4 receptor (IL-4R) complex in human invasive pituitary adenomas. Neurosci Lett; 2007 Apr 24;417(1):30-5
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and structure of interleukin 4 receptor (IL-4R) complex in human invasive pituitary adenomas.
  • Pituitary adenomas are frequently invasive of surrounding tissues, which adversely affects the surgical outcome and the disease-free survival of patients.
  • In the present study, Interleukin 4 receptor (IL-4R) complex has been investigated to figure out whether the three subunits are overexpressed in human invasive pituitary adenomas.
  • Reverse transcription-polymerase chain reaction (RT-PCR) analysis for interleukin 4 receptor alpha (IL-4Ralpha), interleukin 13 receptor alpha1 (IL-13Ralpha1), interleukin 2 receptor gammac (IL-2Rgammac) were performed on total RNA extracted from 10 non-invasive pituitary adenomas, 30 invasive pituitary adenomas, one glioblastoma multiforme, one normal human pituitary tissue sample and one normal human brain tissue sample.
  • Quantitative real-time PCR and in situ immunofluorescence assay were performed in five invasive functioning pituitary adenoma samples and five invasive nonfunctioning pituitary adenoma samples.
  • RT-PCR analysis for IL-4Ralpha, IL-13Ralpha1 and IL-2Rgammac chains were overexpressed in invasive pituitary adenomas.
  • Our results indicate that human invasive pituitary adenomas express type III IL-4R complex.
  • These receptors may serve as a novel target for immunotoxin therapy in patients with invasive pituitary adenomas who are not amenable to total surgical resection or for recurrent cases.
  • [MeSH-major] Adenoma / immunology. Adenoma / metabolism. Biomarkers, Tumor / genetics. Pituitary Neoplasms / immunology. Pituitary Neoplasms / metabolism. Protein Subunits / genetics. Receptors, Interleukin-4 / genetics
  • [MeSH-minor] Fluorescent Antibody Technique. Humans. Immunotherapy / methods. Immunotherapy / trends. Interleukin Receptor Common gamma Subunit / genetics. Interleukin-13 Receptor alpha1 Subunit / genetics. Neoplasm Invasiveness / diagnosis. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / immunology. Predictive Value of Tests. RNA, Messenger / analysis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17398005.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IL2RG protein, human; 0 / Interleukin Receptor Common gamma Subunit; 0 / Interleukin-13 Receptor alpha1 Subunit; 0 / Protein Subunits; 0 / RNA, Messenger; 0 / Receptors, Interleukin-4
  •  go-up   go-down


16. Otake T, Uezono K, Takahashi R, Fukumoto J, Tabata S, Abe H, Tajima O, Mizoue T, Ohnaka K, Kono S: C-reactive protein and colorectal adenomas: Self Defense Forces Health Study. Cancer Sci; 2009 Apr;100(4):709-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-reactive protein and colorectal adenomas: Self Defense Forces Health Study.
  • Several studies have investigated the relationship between C-reactive protein (CRP), a biomarker of inflammation, and colorectal cancer and adenomas, resulting in inconsistent findings.
  • The present study examined the relationship between circulating levels of high-sensitivity CRP and colorectal adenomas.
  • The study subjects comprised 646 cases of colorectal adenoma and 635 controls of normal total colonoscopy among men receiving a preretirement health examination at two hospitals of the Self Defense Forces.
  • The multivariate-adjusted geometric means showed no measurable differences between adenoma cases and controls, but were higher among cases with larger adenomas (trend P = 0.03).
  • Likewise, although the prevalence odds of colorectal adenomas did not differ according to CRP levels as categorized at the 30th, 60th, and 90th percentiles in the controls, higher levels of CRP were associated with a statistically significant increase in the prevalence odds of large adenomas (> or = 5 mm), but not of small adenomas (<5 mm).
  • The multivariate-adjusted odds ratios of large adenomas for the lowest to highest categories of CRP were 1.00 (referent), 1.81 (95% confidence interval 1.17-2.80), 1.61 (95% confidence interval 1.03-2.52), and 2.21 (95% confidence interval 1.28-3.84), respectively (trend P = 0.01).
  • A positive association between CRP and prevalence odds of large adenomas was not modified by either smoking or overweight.
  • These findings suggest that inflammation is linked to the growth of colorectal adenomas.
  • [MeSH-major] Adenoma / genetics. C-Reactive Protein / genetics. Colorectal Neoplasms / genetics. Health Surveys. Military Personnel / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Veterans and Military Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469014.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


17. Bottoni A, Zatelli MC, Ferracin M, Tagliati F, Piccin D, Vignali C, Calin GA, Negrini M, Croce CM, Degli Uberti EC: Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. J Cell Physiol; 2007 Feb;210(2):370-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas.
  • It has been demonstrated that miRNA expression is altered in many human cancers, suggesting that they may play a role in human neoplasia.
  • To determine whether miRNA expression is altered in pituitary adenomas, we analyzed the entire miRNAome in 32 pituitary adenomas and in 6 normal pituitary samples by microarray and by Real-Time PCR.
  • Here, we show that 30 miRNAs are differentially expressed between normal pituitary and pituitary adenomas.
  • Moreover, 24 miRNAs were identified as a predictive signature of pituitary adenoma and 29 miRNAs were able to predict pituitary adenoma histotype. miRNA expression could differentiate micro- from macro-adenomas and treated from non-treated patient samples.
  • Predictive miRNAs could be potentially useful diagnostic markers, improving the classification of pituitary adenomas.
  • [MeSH-major] Adenoma / genetics. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / genetics. Gene Expression Regulation, Neoplastic / genetics. MicroRNAs / genetics. Pituitary Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17111382.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / MicroRNAs; 0 / RNA, Messenger
  •  go-up   go-down


18. Zhongyin Z, Hesheng L, Jun L, Jihong C: Association of serum lipids and apolipoprotein E gene polymorphism with the risk of colorectal adenomas. Saudi Med J; 2006 Feb;27(2):161-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of serum lipids and apolipoprotein E gene polymorphism with the risk of colorectal adenomas.
  • OBJECTIVE: To investigate the relationship of serum lipids and apolipoprotein (apoE) gene polymorphism to colorectal adenomas.
  • Ninety-eight patients with colorectal adenomas and 40 healthy subjects were enrolled, and their serum levels of triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) were determined.
  • RESULTS: Serum TC levels of colorectal adenomas group (5.32 +/- 0.85 mmol/L), distal colorectal adenomas group (5.58 +/- 0.63 mmol/L), and villous adenoma group (5.49 +/- 0.69 mmol/L) were higher than the control group (4.28 +/- 0.62 mmol/L, p=0.016), proximal colorectal adenomas group (4.82 +/- 0.58 mmol/L, p=0.038) and non-villous adenoma group (4.76 +/- 0.58 mmol/L, p=0.03).
  • Serum HDL-C levels of colorectal adenomas group (1.39 +/- 0.25 mmol/L) were lower than the control group (1.51 +/- 0.29 mmol/L) (p=0.035).
  • Serum lipids levels of each genotype in colorectal adenomas group were not statistically significant.
  • Apolipoprotein E3/E4 genotypic frequency in colorectal adenomas group (7.1%) was lower than the control group (17.5%) (p=0.012).
  • CONCLUSION: The findings suggest that altered lipid metabolism may be differentially associated with colorectal adenomas and the persons with apoE E3/E4 genotype have lower risk suffering from colorectal adenomas than those with other genotypes.
  • [MeSH-major] Adenoma / blood. Adenoma / genetics. Apolipoproteins E / genetics. Colorectal Neoplasms / blood. Colorectal Neoplasms / genetics. Lipids / blood

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501668.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Cholesterol, HDL; 0 / Cholesterol, LDL; 0 / Lipids; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


19. Cha JM, Lee JI, Joo KR, Jung SW, Shin HP: A prospective randomized study on computed virtual chromoendoscopy versus conventional colonoscopy for the detection of small colorectal adenomas. Dig Dis Sci; 2010 Aug;55(8):2357-64
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective randomized study on computed virtual chromoendoscopy versus conventional colonoscopy for the detection of small colorectal adenomas.
  • BACKGROUND: Colonoscopy is considered to be the standard diagnostic test for detecting colonic neoplasia, particularly for small lesions.
  • However, recent publications have suggested that 15-27% of small adenomas might be missed during conventional colonoscopy.
  • AIMS: To determine whether computed virtual chromoendoscopy (CVC) can improve the detection of small adenomas as compared to conventional colonoscopy.
  • The groups did not differ in the number of patients with all polyps, adenomas, or hyperplastic polyps.
  • In the patients with adenomas, however, there was a significant difference in the detection rate for the patients with small adenomas less than 5 mm in size (P = 0.006).
  • CONCLUSIONS: Colonoscopy with the CVC mode identified more patients with small colorectal adenomas than conventional white-light colonoscopy.
  • Therefore, CVC might be a supplementary tool aiding the colonoscopist in the detection of small adenomas; however, further studies will need to demonstrate whether these results are reproducible across patients in varied clinical settings.
  • [MeSH-major] Adenoma / diagnosis. Colonoscopy / methods. Colorectal Neoplasms / diagnosis. Endoscopy, Gastrointestinal / methods

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19834809.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Filipe B, Baltazar C, Albuquerque C, Fragoso S, Lage P, Vitoriano I, Mão de Ferro S, Claro I, Rodrigues P, Fidalgo P, Chaves P, Cravo M, Nobre Leitão C: APC or MUTYH mutations account for the majority of clinically well-characterized families with FAP and AFAP phenotype and patients with more than 30 adenomas. Clin Genet; 2009 Sep;76(3):242-55
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] APC or MUTYH mutations account for the majority of clinically well-characterized families with FAP and AFAP phenotype and patients with more than 30 adenomas.
  • Patients presenting familial adenomatous polyposis (FAP), attenuated familial adenomatous polyposis (AFAP) or multiple colorectal adenomas (MCRAs) phenotype are clinically difficult to distinguish.
  • We aimed to genetically characterize 107 clinically well-characterized patients with FAP-like phenotype, and stratified according to the recent guidelines for the clinical management of FAP: FAP, AFAP, MCRA (10-99 colorectal adenomas) without family history of colorectal cancer or few adenomas (FH), MCRA (10-99) with FH, MCRA (3-9) with FH.
  • In 26% of these patients, an MUTYH mutation was identified and the detection rate increased with the number of adenomas, irrespectively of family history, being significantly higher in MCRA patients presenting more than 30 adenomas [7/12 (58%) vs 2/14 (14%), p = 0.023].
  • We validate the recently proposed guidelines in our patient's cohort and show that APC or MUTYH germline defects are responsible for the majority of clinically well-characterized patients with FAP and AFAP phenotype, and patients with more than 30 colorectal adenomas.
  • The different mutation frequencies according to family history and to the number of adenomas underscore the importance of an adequate familial characterization, both clinically and by colonoscopy, in the management of FAP-like phenotypes.
  • [MeSH-major] Adenoma / enzymology. Adenoma / genetics. Adenomatous Polyposis Coli / enzymology. Adenomatous Polyposis Coli / genetics. Adenomatous Polyposis Coli Protein / genetics. DNA Glycosylases / genetics. Mutation / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793053.001).
  • [ISSN] 1399-0004
  • [Journal-full-title] Clinical genetics
  • [ISO-abbreviation] Clin. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / mutY adenine glycosylase
  •  go-up   go-down


21. Dworakowska D, Grossman AB: The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab; 2009 Oct;23(5):525-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pathophysiology of pituitary adenomas.
  • Most pituitary tumours are sporadic, but some arise as a component of genetic syndromes such as the McCune-Albright syndrome, multiple endocrine neoplasia type 1, Carney complex and, the most recently described, a MEN1-like phenotype (MEN4) and pituitary adenoma predisposition syndromes.
  • Some specific genes have been identified that predispose to pituitary neoplasia (GNAS, MEN1, PRKAR1A, CDKN1B and AIP), but these are rarely involved in the pathogenesis of sporadic tumours.
  • Mutations of tumour suppressor genes or oncogenes, as seen in more common cancers, do not seem to play an important role in the great majority of pituitary adenomas.
  • [MeSH-major] Adenoma / etiology. Pituitary Neoplasms / etiology
  • [MeSH-minor] Genes, Tumor Suppressor / physiology. Genes, cdc / physiology. Genetic Predisposition to Disease. Humans. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / physiology. Models, Biological. Oncogenes / physiology. Signal Transduction / genetics. Syndrome


22. Kim K, Yoshida D, Teramoto A: Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas. Endocr Pathol; 2005;16(2):115-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas.
  • In malignant tumors, HIF-1alpha upregulates vascular endothelial growth factor (VEGF) expression to induce tumor angiogenesis.
  • Although VEGF and HIF-1alpha are expressed in pituitary adenomas, the relationships of these factors remain unclear.
  • Therefore, we examined the expression of HIF-1alpha and VEGF using real-time RT-PCR and immunohistochemistry to clarify the relationship of these factors in pituitary adenomas.
  • HIF-1alpha mRNA and VEGF mRNA levels in pituitary adenoma tissues from 25 operated patients were quantified using real-time RT-PCR.
  • HIF-1alpha mRNA and protein were expressed in all pituitary adenomas examined.
  • VEGF mRNA and protein were also expressed in all pituitary adenomas.
  • Our results suggest that in pituitary adenomas VEGF expression may not depend strongly on HIF-1alpha expression.
  • [MeSH-major] Adenoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis. Pituitary Neoplasms / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16199896.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


23. Carreiro G, Villela-Nogueira CA, Coelho Hu, Basto S, Pannain VL, Caroli-Bottino A, Ribeiro Filho J: Orthotopic liver transplantation in glucose-6-phosphatase deficiency--Von Gierke disease--with multiple hepatic adenomas and concomitant focal nodular hyperplasia. J Pediatr Endocrinol Metab; 2007 Apr;20(4):545-9
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orthotopic liver transplantation in glucose-6-phosphatase deficiency--Von Gierke disease--with multiple hepatic adenomas and concomitant focal nodular hyperplasia.
  • Von Gierke disease is occasionally complicated by hepatic adenomas (HAs) causing great concern owing to the current difficulties in monitoring them regarding malignant transformation.
  • Orthotopic liver transplantation (OLT) is proposed as a therapeutic tool when multiple HAs and poor metabolic control are present, owing to the lack of a clear-cut criterion to detect early malignant transformation, whether or not associated with growth retardation.
  • Focal nodular hyperplasia (FNH) has never been described together with multiple adenomas in von Gierke disease.
  • We report a 26-year-old woman with von Gierke disease complicated by multiple HAs concomitant with FNH who underwent OLT and is now free from disease symptoms with good long-term outcome.
  • In conclusion, although FNH could have been managed clinically, when multiple adenomas are present, OLT should be planned for some patients, mainly for those with poor metabolic control.
  • [MeSH-major] Adenoma / complications. Focal Nodular Hyperplasia / complications. Glycogen Storage Disease Type I / complications. Glycogen Storage Disease Type I / therapy. Liver Neoplasms / complications. Liver Transplantation


24. Parra-Blanco A, Gimeno-García AZ, Nicolás-Pérez D, García C, Medina C, Díaz-Flores L, Grosso B, Jiménez A, Quintero E: Risk for high-grade dysplasia or invasive carcinoma in colorectal flat adenomas in a Spanish population. Gastroenterol Hepatol; 2006 Dec;29(10):602-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk for high-grade dysplasia or invasive carcinoma in colorectal flat adenomas in a Spanish population.
  • AIM: to determine the frequency and malignancy risk of colonic flat adenomas among patients with colorectal polyps in a Spanish population.
  • RESULTS: 490 polyps (76.6%) were adenomas and 150 (23.4%) hyperplastic; 114 (23.3%) adenomas were flat (3 flat-depressed) whereas 376 (76.7%) were protruding.
  • The diameter of flat and protruding adenomas was 9.2 +/- 7.9. mm and 7.0 +/- 5.9 mm, respectively (p < 0.001).
  • A proximal location was more frequent for flat (63.1%) than for protruding adenomas (48.7%) (p = 0.003).
  • The rate of HGD or SIC was significantly higher in flat than in protruding adenomas (7.0 vs 2.6%; p < 0.04).
  • Flat adenomas had an increased risk for HGD or SIC (OR = 2,7; CI, 1,04-7,04; p < 0.05).
  • CONCLUSIONS: In a Spanish population, flat adenomas represent nearly one quarter of all colorectal neoplastic polyps, their most frequent location being the right colon and they bear a higher risk of malignancy than protruding adenomas, especially for the flat depressed type.
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Colonic Polyps / pathology. Colorectal Neoplasms / pathology
  • [MeSH-minor] Colonoscopy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Risk Factors. Spain

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198636.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  •  go-up   go-down


25. Ruebel KH, Leontovich AA, Jin L, Stilling GA, Zhang H, Qian X, Nakamura N, Scheithauer BW, Kovacs K, Lloyd RV: Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression. Endocrine; 2006 Jun;29(3):435-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression.
  • Very few of the genes that are important in pituitary tumor initiation, progression, and metastasis have been identified to date.
  • To identify potential genes that may be important in pituitary tumor progression and carcinoma development, we used Affymetrix GeneChip HGU-133A-oligonucleotide arrays, which contain more than 15,000 characterized genes from the human genome to study gene expression in an ACTH pituitary carcinoma metastatic to the liver and four pituitary adenomas.
  • Reverse-transcriptase real-time quantitative- PCR (RT-qPCR) was then used to analyze 4 nonneoplastic pituitaries, 19 adenomas, and the ACTH carcinoma.
  • A larger series of pituitary adenomas and carcinomas were also analyzed for protein expression using tissue microarrays (TMA) (n = 233) and by Western blotting (n = 18).
  • There were 4298 genes that were differentially expressed among the adenomas compared to the carcinoma, with 2057 genes overexpressed and 2241 genes underexpressed in the adenomas.
  • The beta-galactoside binding protein galactin-3 was underexpressed in some adenomas compared to the carcinomas.
  • The human achaetescute homolog-1 ASCL1 (hASH-1) gene was also underexpressed in some adenomas compared to the carcinoma.
  • ID2, which has an important role in cell development and tumorigenesis, was underexpressed in some adenomas compared to the carcinomas.
  • Transducin-like enhancer of split four/ Groucho (TLE-4) was over-expressed in adenomas compared to the ACTH carcinoma.
  • [MeSH-major] Adenoma / genetics. Carcinoma / genetics. Gene Expression Profiling / methods. Oligonucleotide Array Sequence Analysis / methods. Pituitary Neoplasms / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / metabolism. Blotting, Western. DNA-Binding Proteins / metabolism. Follicle Stimulating Hormone / secretion. GRB2 Adaptor Protein / metabolism. Growth Hormone-Secreting Pituitary Adenoma / metabolism. Humans. Immunohistochemistry. Inhibitor of Differentiation Protein 2 / metabolism. Luteinizing Hormone / secretion. Nuclear Proteins / metabolism. Prolactinoma / metabolism. Repressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MENOTROPINS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16943582.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 90249
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / GRB2 Adaptor Protein; 0 / GRB2 protein, human; 0 / ID2 protein, human; 0 / Inhibitor of Differentiation Protein 2; 0 / Nuclear Proteins; 0 / Repressor Proteins; 0 / TLE4 protein, human; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


26. Qualtrough D, Singh K, Banu N, Paraskeva C, Pignatelli M: The actin-bundling protein fascin is overexpressed in colorectal adenomas and promotes motility in adenoma cells in vitro. Br J Cancer; 2009 Oct 6;101(7):1124-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The actin-bundling protein fascin is overexpressed in colorectal adenomas and promotes motility in adenoma cells in vitro.
  • BACKGROUND: Fascin is overexpressed in many cancers, including colorectal, but its role in the malignant transformation of benign colorectal adenomas is unclear.
  • METHODS: Immunohistochemical analysis of fascin expression was carried out in resected human colorectal adenoma specimens.
  • The effects of forced overexpression of fascin on adenoma cell motility were also analysed.
  • RESULTS: We show fascin overexpression in adenomas increasing with tumour size, histological type, and degree of dysplasia and increased cell motility in adenoma cell lines following fascin transfection.
  • [MeSH-major] Adenoma / pathology. Carrier Proteins / physiology. Colorectal Neoplasms / pathology. Microfilament Proteins / physiology
  • [MeSH-minor] Cell Line, Tumor. Cell Movement. Disease Progression. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2000 Nov 18;321(7271):1278-81 [11082094.001]
  • [Cites] Int J Cancer. 2007 Aug 15;121(4):734-40 [17437271.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] Cancer Res. 1976 Dec;36(12):4562-9 [1000501.001]
  • [Cites] Int J Cancer. 1984 Jul 15;34(1):49-56 [6746117.001]
  • [Cites] Cancer Res. 1989 Mar 1;49(5):1282-6 [2917357.001]
  • [Cites] Semin Cell Biol. 1994 Jun;5(3):165-74 [7919230.001]
  • [Cites] Lancet. 1996 May 18;347(9012):1377-81 [8637346.001]
  • [Cites] Oncogene. 1997 Jan 23;14(3):283-93 [9018114.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]
  • [Cites] BMC Cancer. 2006;6:241 [17029629.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1118-26 [17375048.001]
  • [Cites] Cell Mol Life Sci. 2001 Mar;58(3):371-92 [11315186.001]
  • (PMID = 19738613.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / FSCN1 protein, human; 0 / Microfilament Proteins
  • [Other-IDs] NLM/ PMC2768091
  •  go-up   go-down


27. Fougner SL, Lekva T, Borota OC, Hald JK, Bollerslev J, Berg JP: The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab; 2010 May;95(5):2334-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response.
  • In somatotroph adenomas, a variable and reduced expression of E-cadherin has been demonstrated.
  • In addition, nuclear translocation of E-cadherin was found to correlate with pituitary tumor invasion.
  • OBJECTIVE: The objective was to examine the protein expression of E-cadherin in somatotroph pituitary adenomas in relation to adenoma size, invasiveness, and somatostatin analog (SMS) efficacy.
  • Adenoma E-cadherin protein expression was analyzed by Western blot (61 patients) and immunohistochemistry (IHC) (80 patients) with antibodies directed against both extracellular and intracellular domains (IHC).
  • Baseline tumor volume and invasiveness were measured on magnetic resonance imaging scans.
  • RESULTS: Membranous E-cadherin was lost in several adenomas.
  • The E-cadherin protein expression correlated negatively to tumor size and positively to acute SMS response.
  • Low E-cadherin levels (preoperatively treated group only) and loss of membranous E-cadherin correlated to tumor invasiveness.
  • The E-cadherin level correlated positively to tumor reduction after SMS treatment, and adenomas with nuclear E-cadherin staining had lower IGF-I reduction and tumor shrinkage.
  • Preoperatively treated adenomas had reduced E-cadherin protein levels, but the IHC expression was unaltered.
  • CONCLUSION: Reduced E-cadherin expression may correlate to a dedifferentiated phenotype in the somatotroph pituitary adenomas.
  • [MeSH-minor] Acromegaly / complications. Acromegaly / surgery. Adult. Female. Growth Hormone / blood. Humans. Immunohistochemistry. Insulin-Like Growth Factor I / metabolism. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness


28. Evang JA, Borota OC, Melum E, Holm R, Ramm-Pettersen J, Bollerslev J, Berg JP: HDAC2 expression and variable number of repeats in exon 1 of the HDAC2 gene in corticotroph adenomas. Clin Endocrinol (Oxf); 2010 Aug;73(2):229-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HDAC2 expression and variable number of repeats in exon 1 of the HDAC2 gene in corticotroph adenomas.
  • OBJECTIVES: Alterations in protein expression of histone deacetylase 2 (HDAC2) have been demonstrated in various neoplasms, and lack of nuclear expression of HDAC2 has previously been shown in some human and canine corticotroph adenomas.
  • This study aimed to examine HDAC2 expression in a Norwegian cohort of corticotroph adenomas, screen for exonic HDAC2 gene variants in the adenomas and correlate the results with clinical data.
  • PATIENTS AND DESIGN: Forty-four patients with verified Cushing's disease or Nelson's syndrome, positive ACTH staining and tissue available for immunohistochemistry and/or DNA sequencing were included.
  • RESULTS: Histone deacetylase 2 expression examined by immunohistochemistry was strongly reduced in 3/30 adenomas.
  • A previously unidentified insertion of three bases in a region coding for a polyserine cluster in exon 1 of the HDAC2 gene was identified in 6/32 adenomas.
  • Mutations in HDAC2 exons are unlikely to play an important role in the development of corticotroph adenomas.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / genetics. Adenoma / genetics. Histone Deacetylase 2 / genetics. Minisatellite Repeats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20346000.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.5.1.98 / HDAC2 protein, human; EC 3.5.1.98 / Histone Deacetylase 2
  •  go-up   go-down


29. Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H, Suganuma M, Fujiki H, Moriwaki H: Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev; 2008 Nov;17(11):3020-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study.
  • Because colorectal adenomas are the precursors to most sporadic colorectal cancers, we conducted a randomized trial to determine the preventive effect of GTE supplements on metachronous colorectal adenomas by raising green tea consumption in the target population from an average of 6 cups (1.5 g GTE) daily to > or = 10 cups equivalent (2.5 g GTE) by supplemental GTE tablets.
  • METHODS: We recruited 136 patients, removed their colorectal adenomas by endoscopic polypectomy, and 1 year later confirmed the clean colon (i.e., no polyp) at the second colonoscopy.
  • RESULTS: The incidence of metachronous adenomas at the end-point colonoscopy was 31% (20 of 65) in the control group and 15% (9 of 60) in the GTE group (relative risk, 0.49; 95% confidence interval, 0.24-0.99; P < 0.05).
  • The size of relapsed adenomas was also smaller in the GTE group than in the control group (P < 0.001).
  • CONCLUSION: GTE is an effective supplement for the chemoprevention of metachronous colorectal adenomas.
  • [MeSH-major] Adenoma / prevention & control. Colorectal Neoplasms / prevention & control. Neoplasms, Second Primary / prevention & control. Plant Extracts. Tea

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Green tea .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18990744.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Tea
  •  go-up   go-down


30. Liao KF, Lai HC, Lai SW, Cheng KC, Lin CH: Association between rectosigmoid adenomas and cardiovascular risk factors: a hospital-based, cross-sectional study. Ann Acad Med Singapore; 2009 Jul;38(7):630-6
MedlinePlus Health Information. consumer health - Triglycerides.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between rectosigmoid adenomas and cardiovascular risk factors: a hospital-based, cross-sectional study.
  • INTRODUCTION: Little was known about the association between colorectal adenomas and cardiovascular risk factors in Taiwan.
  • The aim of this study was to assess the association between rectosigmoid adenomas and related factors.
  • RESULTS: In the fi nal model, increasing age (OR, 1.05; 95% CI, 1.03-1.06), hypertriglyceridemia (OR, 1.49; 95% CI, 1.07-2.07), and alcohol consumption (OR, 2.11; 95% CI, 1.47-3.04) were the risk factors for rectosigmoid adenomas in men.
  • Increasing age was the only risk factor for rectosigmoid adenomas in women (OR, 1.03; 95% CI, 1.01-1.06).
  • CONCLUSION: Age, hypertriglyceridemia and alcohol consumption are associated with rectosigmoid adenomas in men, and only age is significantly associated with rectosigmoid adenomas in women.
  • [MeSH-major] Adenoma / complications. Alcohol Drinking / adverse effects. Hypertriglyceridemia / complications. Rectal Neoplasms / complications. Sigmoid Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Alcohol.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652855.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


31. Hou XZ, Liu W, Fan HT, Liu B, Pang B, Xin T, Xu SC, Pang Q: Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas. Neuro Oncol; 2010 Aug;12(8):799-803
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas.
  • But little is known about their expression in pituitary adenomas.
  • In this study, the expression of HGF and c-Met in pituitary adenomas of different histology types was investigated by immunohistochemistry, and correlative analysis of their expression with microvessel density (MVD), Ki-67 expression, and other clinicopathologic factors was made.
  • The results showed that the expression of HGF and c-Met exists in 98% (64 of 65) and 92% (60 of 65) pituitary adenomas, respectively, and co-expression of them existed in 91% (59 of 65) adenomas.
  • There were no significant differences in HGF and c-Met expression between pituitary adenomas of different histology types.
  • The results indicate that HGF and c-Met are widely expressed in pituitary adenomas, and their expression correlates with MVD and Ki-67 expression.
  • [MeSH-major] Adenoma / metabolism. Adenoma / pathology. Hepatocyte Growth Factor / biosynthesis. Pituitary Neoplasms / metabolism. Pituitary Neoplasms / pathology. Proto-Oncogene Proteins c-met / biosynthesis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 1998 Feb 27;124(2):149-55 [9500204.001]
  • [Cites] Int J Cancer. 1998 Jan 5;75(1):19-28 [9426685.001]
  • [Cites] Neurochirurgie. 1998 Mar;44(1):25-30 [9757314.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):10-8 [9988225.001]
  • [Cites] Pathol Res Pract. 1999;195(6):427-33 [10399184.001]
  • [Cites] Oncol Rep. 1999 Sep-Oct;6(5):1051-6 [10425302.001]
  • [Cites] Mol Biol Cell. 2005 Feb;16(2):550-61 [15548598.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):436-51 [16212809.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9355-62 [16230398.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):179-88 [17047381.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3529-34 [17440059.001]
  • [Cites] Neuropathology. 2007 Apr;27(2):114-20 [17494511.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):830-41 [17316758.001]
  • [Cites] Int J Oncol. 2007 Jul;31(1):49-58 [17549404.001]
  • [Cites] Front Biosci. 2008;13:1943-51 [17981681.001]
  • [Cites] Hum Pathol. 2008 May;39(5):758-66 [18439942.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4360-8 [18519697.001]
  • [Cites] Histopathology. 2008 Jul;53(1):39-47 [18613924.001]
  • [Cites] Cancer. 2009 Jan 1;115(1):140-8 [18973197.001]
  • [Cites] Eur J Haematol. 2009 Apr;82(4):277-87 [19187270.001]
  • [Cites] Hum Pathol. 2009 Apr;40(4):496-504 [19121849.001]
  • [Cites] Anat Rec (Hoboken). 2009 Aug;292(8):1114-21 [19533745.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):517-30 [10571413.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):287-93 [10873600.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4277-83 [10945642.001]
  • [Cites] J Neurosurg Sci. 2000 Dec;44(4):203-9; discussion 209-10 [11327289.001]
  • [Cites] FASEB J. 2002 Jan;16(1):108-10 [11729097.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2703-15 [11909963.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3210-8 [12115353.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jul;129(7):415-22 [14605882.001]
  • [Cites] Oncogene. 2003 Nov 20;22(52):8498-508 [14627990.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1063-9 [15154624.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):914-20 [15223962.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3a):1797-804 [15274358.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6109-18 [15342394.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):477-81 [7531224.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 1;87(21):1603-12 [7563203.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1809-13 [8625052.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] Oncology. 1996 Sep-Oct;53(5):392-7 [8784474.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5391-8 [9393765.001]
  • [Cites] Histopathology. 1997 Nov;31(5):436-43 [9416484.001]
  • [Cites] Virchows Arch. 1998 Apr;432(4):331-5 [9565342.001]
  • (PMID = 20200025.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  • [Other-IDs] NLM/ PMC2940671
  •  go-up   go-down


32. Sheehan JP, Niranjan A, Sheehan JM, Jane JA Jr, Laws ER, Kondziolka D, Flickinger J, Landolt AM, Loeffler JS, Lunsford LD: Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg; 2005 Apr;102(4):678-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium.
  • OBJECT: Pituitary adenomas are very common neoplasms, constituting between 10 and 20% of all primary brain tumors.
  • Historically, the treatment armamentarium for pituitary adenomas has included medical management, microsurgery, and fractionated radiotherapy.
  • The goal of this research was to define more fully the efficacy, safety, and role of radiosurgery in the treatment of pituitary adenomas.
  • METHODS: Medical literature databases were searched for articles pertaining to pituitary adenomas and stereotactic radiosurgery.
  • Each study was examined to determine the number of patients, radiosurgical parameters (for example, maximal dose and tumor margin dose), duration of follow-up review, tumor growth control rate, complications, and rate of hormone normalization in the case of functioning adenomas.
  • Radiosurgery resulted in the control of tumor size in approximately 90% of treated patients.
  • The reported rates of hormone normalization for functioning adenomas varied substantially.
  • The risks of hypopituitarism, radiation-induced neoplasia, and cerebral vasculopathy associated with radiosurgery appeared lower than those for fractionated radiation therapy.
  • CONCLUSIONS: Although microsurgery remains the primary treatment modality in most cases, stereotactic radiosurgery offers both safe and effective treatment for recurrent or residual pituitary adenomas.
  • In rare instances, radiosurgery may be the best initial treatment for patients with pituitary adenomas.
  • [MeSH-major] Adenoma / surgery. Pituitary Neoplasms / surgery. Radiosurgery / adverse effects. Radiosurgery / methods

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15871511.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 123
  •  go-up   go-down


33. Karabatsou K, O'Kelly C, Ganna A, Dehdashti AR, Gentili F: Outcomes and quality of life assessment in patients undergoing endoscopic surgery for pituitary adenomas. Br J Neurosurg; 2008 Oct;22(5):630-5
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and quality of life assessment in patients undergoing endoscopic surgery for pituitary adenomas.
  • The endoscopic technique is increasingly being used for the resection of pituitary adenomas.
  • Most of the studies assessing the quality of life after long-term cure of pituitary adenomas suggest a significantly impaired quality of life (QoL) in all subgroups of pituitary tumours.
  • The validated health questionnaire SF-36 was sent to 80 patients who had undergone pure endoscopic resection of a pituitary adenoma.
  • We also compared the results amongst different types of adenomas.
  • Our study suggests only minimal impairment of quality of life in patients after successful treatment of pituitary adenomas using the endoscopic approach.
  • There were only very few differences in the perceived quality of life within the different subgroups of adenomas.
  • Whilst our data suggest minimal impact on the quality of life for patients after endoscopic removal of pituitary adenomas, further studies with larger number of patients and longer follow-up are required to encourage this finding.
  • [MeSH-major] Adenoma / surgery. Endoscopy / methods. Pituitary Neoplasms / surgery. Quality of Life

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18686060.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


34. Spinazzi R, Rucinski M, Neri G, Malendowicz LK, Nussdorfer GG: Preproorexin and orexin receptors are expressed in cortisol-secreting adrenocortical adenomas, and orexins stimulate in vitro cortisol secretion and growth of tumor cells. J Clin Endocrinol Metab; 2005 Jun;90(6):3544-9
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preproorexin and orexin receptors are expressed in cortisol-secreting adrenocortical adenomas, and orexins stimulate in vitro cortisol secretion and growth of tumor cells.
  • In this study, we demonstrate that six of eight cortisol-secreting adenomas expressed preproorexin mRNA, and seven of 10 adenomas contained measurable amounts of orexin-A but not orexin-B.
  • All adenomas expressed OX1-R and OX2-R mRNAs, and real-time PCR showed that the expression of both receptors was up-regulated in adenomas, compared with normal adrenal cortex.
  • Orexin-A concentration-dependently raised basal cortisol secretion from freshly dispersed normal and adenomatous cells, minimal and maximal effective concentrations being 10(-10) and 10(-8) m, and the peptide efficacy (percent increase elicited by 10(-8) m orexin-A) was significantly higher in adenomas than in the normal adrenal cortex.
  • In contrast, both orexins (10(-8) m) raised the proliferative activity of cultured normal and adenomatous cells, suggesting that this effect is mediated by OX2-R or both receptor subtypes.
  • Collectively, our findings allow us to conclude that the orexin system is overexpressed in cortisol-secreting adenomas and suggest that orexin-A may act as an autocrine-paracrine regulator of the secretory activity and growth of some of these adrenal tumors.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenocortical Adenoma / genetics. Hydrocortisone / secretion. Receptors, Neuropeptide / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15797953.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Complementary; 0 / HCRT protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neuropeptides; 0 / Orexin Receptors; 0 / Orexins; 0 / RNA, Messenger; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Neuropeptide; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


35. Moran JA, Lemberger K, Cadoré JL, Lepage OM: Small intestine adenocarcinoma in conjunction with multiple adenomas causing acute colic in a horse. J Vet Diagn Invest; 2008 Jan;20(1):121-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small intestine adenocarcinoma in conjunction with multiple adenomas causing acute colic in a horse.
  • Histologic examination revealed an adenocarcinoma and multiple polypoid adenomas.
  • Adenocarcinoma recurrence or transformation from remaining adenomas into an adenocarcinoma is still a major risk.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182527.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Leung AM, Sasano H, Nishikwa T, McAneny DB, Malabanan AO: Multiple unilateral adrenal adenomas in a patient with primary hyperaldosteronism. Endocr Pract; 2008 Jan-Feb;14(1):76-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple unilateral adrenal adenomas in a patient with primary hyperaldosteronism.
  • OBJECTIVE: To report a rare case of multiple unilateral adrenal adenomas in which immunohistochemistry results confirmed primary hyperaldosteronism in each of 3 adenomas.
  • METHODS: We present the clinical, laboratory, radiographic, and pathologic findings of a case of multiple unilateral adrenal adenomas.
  • A 45-year-old woman with a long-standing history of severe hypertension was found to have biochemical parameters consistent with primary hyperaldosteronism, multiple unilateral adrenal adenomas, and immunohistochemical test results confirming primary hyperaldosteronism arising from each of 3 adrenal nodules (measuring 2.2 x 2.2 cm, 1.7 x 0.7 cm, and 0.5 x 0.5 cm).
  • CONCLUSION: This case illustrates the rare presentation of primary hyperaldosteronism as multiple unilateral adrenal adenomas in which immunohistochemistry results can confirm the suspected preoperative diagnosis as suggested by biochemical and radiographic evidence.
  • [MeSH-major] Adenoma / complications. Adrenal Gland Neoplasms / complications. Hyperaldosteronism / etiology

  • Genetic Alliance. consumer health - Hyperaldosteronism.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18238744.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 4964P6T9RB / Aldosterone
  •  go-up   go-down


37. Saebø M, Skjelbred CF, Brekke Li K, Bowitz Lothe IM, Hagen PC, Johnsen E, Tveit KM, Kure EH: CYP1A2 164 A--&gt;C polymorphism, cigarette smoking, consumption of well-done red meat and risk of developing colorectal adenomas and carcinomas. Anticancer Res; 2008 Jul-Aug;28(4C):2289-95
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CYP1A2 164 A-->C polymorphism, cigarette smoking, consumption of well-done red meat and risk of developing colorectal adenomas and carcinomas.
  • BACKGROUND: Genetic polymorphisms in metabolizing enzymes may modify the association of environmental exposure on colorectal cancer (CRC) and adenoma risk.
  • MATERIALS AND METHODS: One hundred and ninety-eight CRC cases, 422 adenomas (206 low-risk and 216 high-risk adenomas) and 222 controls were genotyped for the CYP1A2 164 A-->C polymorphism and questionnaires were used to assess environmental exposure.
  • RESULTS: The smoking parameter "current smoking" was significantly associated with CRC risk, and all the smoking parameters related to current smoking, having ever smoked or high numbers of cigarette years were significantly associated with risk of adenomas.
  • [MeSH-major] Adenoma / etiology. Colorectal Neoplasms / etiology. Cytochrome P-450 CYP1A2 / genetics. Diet. Meat. Smoking

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751408.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 1.14.14.1 / CYP1A2 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1A2
  •  go-up   go-down


38. Sinha S, Sharma BS: Giant pituitary adenomas--an enigma revisited. Microsurgical treatment strategies and outcome in a series of 250 patients. Br J Neurosurg; 2010 Feb;24(1):31-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant pituitary adenomas--an enigma revisited. Microsurgical treatment strategies and outcome in a series of 250 patients.
  • BACKGROUND: Giant pituitary adenomas (> 4 cm) are a surgical challenge.
  • METHODS: Two hundred and fifty patients with giant pituitary adenomas were managed surgically at our center over last 13 years.
  • Among functioning adenomas, 63 patients (25.4%) had prolactinomas and 45 patients (18%) had GH-secreting adenomas; while 3 patients each had LH and ACTH- secreting adenomas.
  • The maximum tumor diameter varied from 4 to 10.5 cm, with mean diameter of 5.4 cm.
  • 23 patients (9.2%) underwent re-exploration either because of postoperative apoplexy or residual tumor.
  • Overall, near total (>90%) tumor excision could be achieved in 74%, with improved vision in 53% and good outcome in 75% patients.
  • CONCLUSIONS: The main goal of surgical treatment of giant pituitary adenoma is maximum possible tumor extirpation with minimal side effects, which can be achieved by careful preoperative planning of operative approach, based on directions of tumor extensions and invasiveness.
  • Maximal surgical removal of giant adenomas offers best chances to control tumor growth when followed with adjuvant medical and radiation therapies.
  • [MeSH-major] Adenoma / surgery. Microsurgery / methods. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20158350.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Anderson JC, Stein B, Kahi CJ, Rajapakse R, Walker G, Alpern Z: Association of smoking and flat adenomas: results from an asymptomatic population screened with a high-definition colonoscope. Gastrointest Endosc; 2010 Jun;71(7):1234-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of smoking and flat adenomas: results from an asymptomatic population screened with a high-definition colonoscope.
  • BACKGROUND: Flat adenomas represent a morphologically distinct class of polyps that may be difficult to detect, and little is known regarding risk factors for these lesions.
  • Smoking, an important risk factor for CRC, may be associated with molecular changes that increase the risk for flat adenomas.
  • OBJECTIVE: The aim of this study was to examine the association between smoking and flat adenomas.
  • We observed that smoking was associated with having a flat adenoma of any size (adjusted odds ratio [OR], 2.53; 95% CI, 1.60-4.00), having only flat adenomas that were > or = 6 mm in diameter (adjusted OR, 3.84; 95% CI, 2.02-7.32), as well as flat advanced adenomas (adjusted OR, 2.81; 95% CI, 1.08-7.30).
  • LIMITATIONS: The study design may not account for some confounding variables and provides no information regarding smoking status at the time of initiation of flat adenomas.
  • CONCLUSION: Smoking was associated with flat adenomas in our population.
  • Smokers may require screening with high-definition colonoscopes to detect flat adenomas.

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
  • [Cites] J Gastroenterol Hepatol. 2000 Mar;15 Suppl:D66-70 [10759223.001]
  • [Cites] Colorectal Dis. 2010 May;12(5):471-6 [19298579.001]
  • [Cites] Lancet. 2000 Apr 8;355(9211):1211-4 [10770302.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 6;92(23):1888-96 [11106680.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1831-6 [11078760.001]
  • [Cites] Dis Colon Rectum. 2001 Feb;44(2):163-6 [11227930.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2676-83 [11289147.001]
  • [Cites] Cancer Detect Prev. 2001;25(5):430-8 [11718449.001]
  • [Cites] Endoscopy. 2001 Dec;33(12):1001-6 [11740641.001]
  • [Cites] Gut. 2002 Oct;51(4):550-5 [12235079.001]
  • [Cites] Gastrointest Endosc. 2003 Dec;58(6 Suppl):S3-43 [14652541.001]
  • [Cites] JAMA. 2003 Dec 10;290(22):2959-67 [14665657.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2777-83 [14687832.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):288-93 [14716762.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Oct;2(10):905-11 [15476154.001]
  • [Cites] AJR Am J Roentgenol. 2004 Nov;183(5):1343-7 [15505301.001]
  • [Cites] Dis Colon Rectum. 1985 Nov;28(11):847-51 [4053897.001]
  • [Cites] Hum Biol. 1987 Aug;59(4):631-9 [3623509.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 2;86(3):183-91 [8283490.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 2;86(3):192-9 [8283491.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1118-20 [7577004.001]
  • [Cites] Cancer Causes Control. 1997 Jul;8(4):610-4 [9242477.001]
  • [Cites] Gastrointest Endosc. 1997 Dec;46(6):492-6 [9434214.001]
  • [Cites] Endoscopy. 2005 Jun;37(6):570-8 [15933932.001]
  • [Cites] Am J Gastroenterol. 2005 Sep;100(9):1903-5; discussion 1907-8 [16128927.001]
  • [Cites] Am J Gastroenterol. 2006 Jan;101(1):172-80 [16405551.001]
  • [Cites] Arch Intern Med. 2006 Mar 27;166(6):629-34 [16567601.001]
  • [Cites] Am J Gastroenterol. 2006 Jun;101(6):1313-9 [16771955.001]
  • [Cites] Gastroenterology. 2006 Aug;131(2):379-89 [16890591.001]
  • [Cites] Cancer Sci. 2006 Dec;97(12):1335-42 [17032312.001]
  • [Cites] Dis Colon Rectum. 2006 Dec;49(12):1893-6 [17096180.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 6;98(23):1731-8 [17148775.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):139-47 [17143260.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3551-4 [17440063.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):42-7 [17631129.001]
  • [Cites] Colorectal Dis. 2007 Sep;9(7):641-6 [17824982.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 21;99(22):1729-35 [18000222.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):43-9; discussion 49 [18034359.001]
  • [Cites] JAMA. 2008 Mar 5;299(9):1027-35 [18319413.001]
  • [Cites] Scand J Gastroenterol. 2008;43(9):1116-21 [18609172.001]
  • [Cites] Gastrointest Endosc. 2008 Oct;68(4 Suppl):S3-47 [18805238.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1062-8 [18725223.001]
  • [Cites] Ann Intern Med. 2009 Jan 6;150(1):1-8 [19075198.001]
  • [Cites] Am J Gastroenterol. 2009 Mar;104(3):739-50 [19240699.001]
  • [Cites] Int J Cancer. 2009 Jul 1;125(1):158-64 [19358278.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Jul;7(7):770-5; quiz 711 [19268269.001]
  • [Cites] J Clin Gastroenterol. 2009 Sep;43(8):747-52 [19407663.001]
  • [CommentIn] Gastrointest Endosc. 2010 Jun;71(7):1241-3 [20598250.001]
  • (PMID = 20417931.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR010710; United States / NCRR NIH HHS / RR / RR010710-09; United States / NCRR NIH HHS / RR / M01 RR010710-09; United States / NCRR NIH HHS / RR / MO1RR10710
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS200247; NLM/ PMC2897970
  •  go-up   go-down


40. Oka S, Tanaka S, Yoshida S, Hiyama T, Ueno Y, Ito M, Kitadai Y, Yoshihara M, Chayama K: A water-soluble extract from culture medium of Ganoderma lucidum mycelia suppresses the development of colorectal adenomas. Hiroshima J Med Sci; 2010 Mar;59(1):1-6
Hazardous Substances Data Bank. Water .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A water-soluble extract from culture medium of Ganoderma lucidum mycelia suppresses the development of colorectal adenomas.
  • To confirm cancer-preventive effects of MAK, we performed a no-treatment concurrent controlled trial on patients with colorectal adenomas.
  • Patients who were determined to be carrying colorectal adenomas by colonoscopy were enrolled in this study.
  • Follow-up colonoscopy was performed after 12 months, and the colonoscopists recorded the size, site and macroscopic type of all adenomas.
  • The changes in the number of adenomas up to 12 months increased to 0.66 +/- 0.10 (mean +/- SE) in the control group, while decreasing in the MAK group to -0.42 +/- 0.10 (p < 0.01).
  • The total size of adenomas increased to 1.73 +/- 0.28 mm in the control group and decreased to -1.40 +/- 0.64 mm in the MAK group (p < 0.01).
  • The resultssuggest that MAK suppresses the development of colorectal adenomas - precancerous lesions of the large bowel.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy. Mycelium / metabolism. Precancerous Conditions / drug therapy. Reishi / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518254.001).
  • [ISSN] 0018-2052
  • [Journal-full-title] Hiroshima journal of medical sciences
  • [ISO-abbreviation] Hiroshima J. Med. Sci.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Culture Media, Conditioned; 059QF0KO0R / Water
  •  go-up   go-down


41. Pawlikowski M, Gruszka A, Kurnatowska I, Winczyk K, Kunert-Radek J, Radek A: Proliferating cell nuclear antigen (PCNA) expression in pituitary adenomas: relationship to the endocrine phenotype of adenoma. Folia Histochem Cytobiol; 2006;44(1):37-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferating cell nuclear antigen (PCNA) expression in pituitary adenomas: relationship to the endocrine phenotype of adenoma.
  • Since proliferation rate is an important factor determining the tumor aggressiveness, the evaluation of PCNA index (the percentage of PCNA-immunopositive nuclei in the investigated tumor sample) is suggested as useful in predicting pituitary adenoma outcome.
  • Seventy three unselected, surgically removed pituitary adenomas were immunostained with antibodies against the pituitary hormones or their subunits and against the proliferating cell nuclear antigen (PCNA).
  • The highest PCNA index was found in ACTH-immunopositive tumors without the manifestation of the Cushing's disease ("silent" corticotropinomas).
  • This value was significantly different in comparison to other adenoma subtypes including corticotropinomas manifesting themselves by Cushing's disease.
  • The adenomas which express more than one hormone (plurihormonal adenomas) seem to have a higher PCNA indices than monohormonal ones; the difference was significant in the case of mono- and plurihormonal prolactinomas.
  • These findings suggest that the proliferative potential of pituitary adenomas is related to the tumor recurrence and hormone expression.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16584090.001).
  • [ISSN] 0239-8508
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Follicle Stimulating Hormone, Human; 0 / Gonadotropins; 0 / Proliferating Cell Nuclear Antigen; 9002-60-2 / Adrenocorticotropic Hormone; 9002-62-4 / Prolactin; 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


42. Sheehan JP, Jagannathan J, Pouratian N, Steiner L: Stereotactic radiosurgery for pituitary adenomas: a review of the literature and our experience. Front Horm Res; 2006;34:185-205
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for pituitary adenomas: a review of the literature and our experience.
  • Pituitary adenomas are not just one of the most common intracranial tumors but also one of the most difficult to cure.
  • Neurosurgeons have adapted their tools to include precise ionizing radiation in the form of the gamma knife to treat pituitary adenomas.
  • The use of the gamma knife in the management of pituitary adenomas following microsurgery or in selected cases as a primary treatment is safe.
  • However in some patients, optimal control of tumor growth and normalization of hypersecretory states are not achieved.
  • Innovative improvements in operative and radiosurgical techniques are required to avoid pituitary insufficiency and to reduce the number of the cases in which optimal radiosurgery is not feasible because of close tumor proximity to the optic pathways.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16474221.001).
  • [ISSN] 0301-3073
  • [Journal-full-title] Frontiers of hormone research
  • [ISO-abbreviation] Front Horm Res
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 75
  •  go-up   go-down


43. Rubio CA, Nesi G, Messerini L, Zampi G: Serrated and microtubular colorectal adenomas in Italian patients. A 5-year survey. Anticancer Res; 2005 Mar-Apr;25(2B):1353-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serrated and microtubular colorectal adenomas in Italian patients. A 5-year survey.
  • Colorectal adenomas from 1552 Italian patients were histologically classified into tubular (TAs), tubulo-villous (TVAs), villous (VAs), serrated (SAs) and microtubular (MTAs).
  • The purpose was to compare the results to those in 3135 colorectal adenomas from Swedish patients.
  • Of the 1552 adenomas, 827 (53%) were TAs, 352 (23%) TVAs, 196 (12%) VAs, 102 (7%), SAs and 14 (0.9%) MTAs.
  • The diameter of the largest section was used to define the size of the largest adenoma in individual patients.
  • SAs and MTAs are special adenoma phenotypes with particular morphological and cell proliferative attributes at variance from those of TAs, VAs or TVAs.
  • In the light of the present results, it is proposed that SAs and MTAs are included in future reports of colorectal adenomas in order to compare their frequency worldwide.
  • [MeSH-major] Adenoma / pathology. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15865091.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


44. Kim DH, Pickhardt PJ, Taylor AJ: Characteristics of advanced adenomas detected at CT colonographic screening: implications for appropriate polyp size thresholds for polypectomy versus surveillance. AJR Am J Roentgenol; 2007 Apr;188(4):940-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of advanced adenomas detected at CT colonographic screening: implications for appropriate polyp size thresholds for polypectomy versus surveillance.
  • OBJECTIVE: Advanced adenomas are the primary target in colorectal screening.
  • The purpose of this study was to delineate the prevalence and imaging characteristics of advanced adenomas detected at screening CT colonography (CTC) and the rates of invasive carcinoma and high-grade dysplasia for various polyp size categories.
  • From this group, prevalence, size, histologic features, morphologic features, and location of advanced adenomas were tabulated.
  • Advanced adenomas were defined by size (> or = 10 mm) and/or histologic findings (prominent villous component or high-grade dysplasia).
  • RESULTS: A total of 123 (38.3%) of 321 adenomas measuring 6 mm or more were classified as advanced, the overall prevalence being 3.1% (111 of 3,536 patients).
  • The mean size of advanced adenomas was 16.6 +/- 11.6 mm; most of the lesions (116/123, 94.3%) qualified as advanced on the basis of the size criterion alone.
  • The seven lesions measuring 6-9 mm constituted 3.4% (7/205) of all medium-sized adenomas.
  • The largest percentage (65/123, 52.8%) of the advanced adenomas had tubular histologic features, followed by tubulovillous (50/123, 40.6%), villous (5/123, 4.1%), and serrated (3/123, 2.4%) histologic features.
  • The majority of advanced adenomas were classified as sessile (57/123, 46.3%) or pedunculated (57/123, 46.3%); a small percentage were flat (9/123, 7.3%).
  • Advanced adenomas were located in the proximal colon in 43.9% (54/123) and distal colon in 56.1% (69/123) of the cases.
  • CONCLUSION: Advanced adenomas were generally large (> or = 10 mm in size); only a small percentage were medium sized (6-9 mm).
  • [MeSH-major] Adenoma / radiography. Colonic Neoplasms / radiography. Colonic Polyps / radiography. Colonography, Computed Tomographic
  • [MeSH-minor] Disease Progression. Female. Humans. Male. Middle Aged. Population Surveillance. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17377027.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Pawlikowski M: Immunohistochemical detection of angiotensin receptors AT1 and AT2 in normal rat pituitary gland, estrogen-induced rat pituitary tumor and human pituitary adenomas. Folia Histochem Cytobiol; 2006;44(3):173-7
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of angiotensin receptors AT1 and AT2 in normal rat pituitary gland, estrogen-induced rat pituitary tumor and human pituitary adenomas.
  • Male rat pituitary glands, diethylstilbestrol (DES)-induced rat pituitary tumors and 12 human pituitary adenomas were immunostained with antibodies raised against AT1 and AT2 angiotensin receptor proteins.
  • In human pituitary adenomas, weak AT1 immunostaining was found in 5 tumors.
  • In the remaining adenomas, the AT1 immunostaining was trace (doubtful) or absent.
  • In human pituitary adenomas, the tumoral cells were AT2- negative but moderate to strong AT2 immunostaining was observed in intratumoral blood vessel walls.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16977796.001).
  • [ISSN] 0239-8508
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Estrogens; 0 / Receptor, Angiotensin, Type 1; 0 / Receptor, Angiotensin, Type 2; 0 / Receptors, Angiotensin; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


46. Rossaak J, Bagshaw P, Connor S: Management of Duodenal Adenomas Involving the Ampulla of Vater - A Warning against Limited Resection. Case Rep Gastroenterol; 2008;2(1):96-102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of Duodenal Adenomas Involving the Ampulla of Vater - A Warning against Limited Resection.
  • Duodenal adenomas are uncommon, however, when present a proportion have dysplasia associated with the adenoma and therefore require treatment.
  • This case report describes two patients with adenomas involving the ampulla of Vater.
  • One patient had familial adenomatous polyposis, the other was a renal transplant patient with a large adenoma.
  • Both patients' adenomas contained high-grade dysplasia.
  • Histology of both specimens demonstrated that the adenoma had migrated up the bile duct for at least 7 mm, and the pancreatic duct for 8 mm in one patient.
  • Limited resection of ampullary adenomas may leave residual adenomatous tissue in the bile duct with the risk of recurrent adenomatous disease and malignant transformation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Yonsei Med J. 2000 Apr;41(2):213-8 [10817022.001]
  • [Cites] Arch Surg. 2002 May;137(5):557-62; discussion 562-3 [11982469.001]
  • [Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):831-7; discussion 837 [12504221.001]
  • [Cites] Ulster Med J. 2002 Nov;71(2):121-7 [12513008.001]
  • [Cites] ANZ J Surg. 2007 May;77(5):371-3 [17497979.001]
  • [Cites] Scand J Gastroenterol. 1994 Jun;29(6):483-7 [8079103.001]
  • [Cites] Br J Surg. 1998 May;85(5):665-8 [9635818.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):493-8 [14752072.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):245-51 [15368108.001]
  • [Cites] J Gastrointest Surg. 2004 Jul-Aug;8(5):559-64 [15239991.001]
  • (PMID = 21490846.001).
  • [ISSN] 1662-0631
  • [Journal-full-title] Case reports in gastroenterology
  • [ISO-abbreviation] Case Rep Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3075174
  • [Keywords] NOTNLM ; Ampullary adenoma/carcinoma / Duodenal adenoma/carcinoma / High-grade dysplasia / Management / Surgery
  •  go-up   go-down


47. Hwang HJ, Song KH, Youn YH, Kwon JE, Kim H, Chung JB, Lee YC: A case of more abundant and dysplastic adenomas in the interposed colon than in the native colon. Yonsei Med J; 2007 Dec 31;48(6):1075-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of more abundant and dysplastic adenomas in the interposed colon than in the native colon.
  • Although synchronous adenomas were also found in the native colon where the graft was taken, the number of adenomas was greater in the interposed colon and more dysplastic, even progressed to adenocarcinoma, than that of the native colon.
  • Changing of location and functional demand of colonic segment, and the exposure to different intraluminal contents might have facilitated the adenoma- carcinoma transformation in the interposed colon.
  • [MeSH-major] Adenoma / pathology. Colon / pathology. Colonic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Disease Progression. Esophagoplasty / adverse effects. Esophagoplasty / methods. Female. Humans. Middle Aged. Postoperative Complications / etiology. Postoperative Complications / pathology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1999 Dec;50(6):852-4 [10570353.001]
  • [Cites] Hepatogastroenterology. 1995 Nov-Dec;42(6):797-9 [8847026.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):209-10 [12867603.001]
  • [Cites] J Am Coll Surg. 2004 Apr;198(4):536-41; discussion 541-2 [15051003.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):748-9 [15143907.001]
  • [Cites] Fam Cancer. 2004;3(2):93-100 [15340259.001]
  • [Cites] Rom J Gastroenterol. 2004 Sep;13(3):187-93 [15470530.001]
  • [Cites] Ann Surg. 1968 Jan;167(1):98-100 [5635190.001]
  • [Cites] Gut. 1967 Dec;8(6):569-73 [6079810.001]
  • [Cites] Lancet. 1978 Feb 4;1(8058):285 [74716.001]
  • [Cites] AJR Am J Roentgenol. 1984 Apr;142(4):703-8 [6608225.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):681-90 [4005819.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2304-7 [3440237.001]
  • [Cites] Gut. 1989 Jun;30(6):880-1 [2753412.001]
  • [Cites] Eur J Surg. 1991 Mar;157(3):189-92 [1678628.001]
  • [Cites] Aust N Z J Surg. 1992 Feb;62(2):158-60 [1586307.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):859-61 [1640334.001]
  • [Cites] J Laryngol Otol. 1994 Jan;108(1):80-3 [8133180.001]
  • [Cites] Dis Colon Rectum. 2000 Apr;43(4):555-8 [10789758.001]
  • (PMID = 18159607.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2628170
  •  go-up   go-down


48. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira A Jr, Gadelha MR, Monson JP, Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M: The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab; 2008 Jun;93(6):2390-401
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas.
  • CONTEXT: Mutations have been identified in the aryl hydrocarbon receptor-interacting protein (AIP) gene in familial isolated pituitary adenomas (FIPA).
  • OBJECTIVE: AIP sequence changes and expression were studied in FIPA and sporadic adenomas.
  • PATIENTS: Twenty-six FIPA kindreds and 85 sporadic pituitary adenoma patients were included in the study.
  • In sporadic pituitary adenomas, however, AIP is expressed in all tumor types.
  • In addition, whereas AIP is expressed in the secretory vesicle in GH-secreting tumors, similar to normal GH-secreting cells, in lactotroph, corticotroph, and nonfunctioning adenomas, it is localized to the cytoplasm and not in the secretory vesicles.
  • CONCLUSIONS: Our functional evaluation of AIP mutations is consistent with a tumor-suppressor role for AIP and its involvement in familial acromegaly.
  • The abnormal expression and subcellular localization of AIP in sporadic pituitary adenomas indicate deranged regulation of this protein during tumorigenesis.
  • [MeSH-major] Adenoma / genetics. Pituitary Neoplasms / genetics. Proteins / physiology
  • [MeSH-minor] Acromegaly / genetics. Acromegaly / metabolism. Adolescent. Adult. Aged. Cell Proliferation. Child. Cyclic Nucleotide Phosphodiesterases, Type 4 / metabolism. Female. Gene Expression Regulation, Neoplastic. Genetic Testing. Human Growth Hormone / secretion. Humans. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Protein Binding. Transfection. Tumor Cells, Cultured


49. Suzuki M, Egashira N, Kajiya H, Minematsu T, Takekoshi S, Tahara S, Sanno N, Teramoto A, Osamura RY: ACTH and alpha-subunit are co-expressed in rare human pituitary corticotroph cell adenomas proposed to originate from ACTH-committed early pituitary progenitor cells. Endocr Pathol; 2008;19(1):17-26
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACTH and alpha-subunit are co-expressed in rare human pituitary corticotroph cell adenomas proposed to originate from ACTH-committed early pituitary progenitor cells.
  • The functional differentiation of pituitary cells and adenomas follows the combination of transcription factors and co-factors in three cell lineages [growth hormone-prolactin-thyroid-stimulating hormone lineage, adrenocorticotrophic hormone (ACTH)/pro-opiomelanocortin (POMC) lineage, and follicular stimulating hormone (FSH)/luteinizing hormone (LH) lineage], which include Pit-1, GATA-2, SF-1, NeuroD1/beta2, Tpit, ERalpha, and others.
  • Only rarely are hormones from different lineages co-expressed in the same adenoma cells.
  • Most corticotroph cell adenomas belonging to the ACTH/POMC lineage are mono-hormonal.
  • In our study of 89 corticotroph cell adenomas, 5 cases expressed both ACTH and alpha-subunit; these adenomas did not express any other anterior pituitary hormones or subunits.
  • As ACTH and alpha-subunit are the earliest hormones to appear during development, we speculate that these particular adenomas are derived from committed ACTH progenitor cells.
  • The molecular process governing functional differentiation of these adenomas requires further investigation.
  • [MeSH-major] Adenoma / genetics. Adrenocorticotropic Hormone / genetics. Gene Expression Regulation, Neoplastic. Glycoprotein Hormones, alpha Subunit / genetics. Pituitary Neoplasms / genetics. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18228160.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Glycoprotein Hormones, alpha Subunit; 0 / NEUROD1 protein, human; 0 / Transcription Factor Pit-1; 0 / Transcription Factors; 66796-54-1 / Pro-Opiomelanocortin; 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


50. Jiang J, Suzuki S, Xiang J, Kuriki K, Hosono A, Arakawa K, Wang J, Nagaya T, Kojima M, Katsuda N, Tokudome S: Plasma carotenoid, alpha-tocopherol and retinol concentrations and risk of colorectal adenomas: A case-control study in Japan. Cancer Lett; 2005 Aug 26;226(2):133-41
Hazardous Substances Data Bank. VITAMIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma carotenoid, alpha-tocopherol and retinol concentrations and risk of colorectal adenomas: A case-control study in Japan.
  • To investigate associations between plasma carotenoids, alpha-tocopherol and retinol with colorectal adenomas risk, we measured concentrations in 224 asymptomatic colorectal adenoma cases and 230 population-based controls matched for age and sex.
  • After adjustment for age, history of colorectal adenomas and cancers, BMI, smoking, drinking status, multivitamin consumption and plasma total cholesterol, the risk of colorectal adenomas in the highest quartile was approximately half of that of men in the lowest quartile for alpha-carotene (OR=0.38; 95% CI: 0.18-0.84; P(trend)=0.01), beta-carotene (OR=0.51; 95% CI: 0.24-1.07; P(trend)=0.03) and total carotenoids (OR=0.48; 95% CI: 0.22-1.03; P(trend)=0.04).
  • Our findings suggest a protective effect of carotenoids against the development of colorectal adenomas.
  • [MeSH-major] Adenoma / blood. Carotenoids / blood. Colorectal Neoplasms / blood. Vitamin A / blood. alpha-Tocopherol / blood

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin A.
  • Hazardous Substances Data Bank. VITAMIN E .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15885891.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 11103-57-4 / Vitamin A; 36-88-4 / Carotenoids; H4N855PNZ1 / alpha-Tocopherol
  •  go-up   go-down


51. van den Donk M, van Engeland M, Pellis L, Witteman BJ, Kok FJ, Keijer J, Kampman E: Dietary folate intake in combination with MTHFR C677T genotype and promoter methylation of tumor suppressor and DNA repair genes in sporadic colorectal adenomas. Cancer Epidemiol Biomarkers Prev; 2007 Feb;16(2):327-33
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary folate intake in combination with MTHFR C677T genotype and promoter methylation of tumor suppressor and DNA repair genes in sporadic colorectal adenomas.
  • Methylation of the promoter region of tumor suppressor genes is increasingly recognized to play a role in cancer development through silencing of gene transcription.
  • We examined the associations between dietary folate intake, MTHFR C677T genotype, and promoter methylation of six tumor suppressor and DNA repair genes.
  • Patients with colorectal adenoma (n = 149) and controls (n = 286) with folate intake in the upper or lower tertile with the CC or TT genotype were selected from a case-control study.
  • Methylation-specific PCRs were conducted on colorectal adenoma specimens.
  • Case-control comparisons suggested that folate was not associated with the occurrence of adenomas with promoter methylation, and increased the risk of unmethylated adenomas, especially in TT homozygotes.
  • The interactions between folate and MTHFR genotype were most pronounced for O(6)-MGMT: compared with CC homozygotes with low folate intake, the adjusted odds ratios (95% confidence interval) of having a methylated O(6)-MGMT promoter were 3.39 (0.82-13.93) for TT homozygotes with low folate intake and 0.37 (0.11-1.29) for TT homozygotes with high folate intake (P interaction = 0.02); the odds ratios for the occurrence of adenomas without methylation were 0.57 (0.16-2.11) for TT homozygotes with low folate intake and 3.37 (1.17-9.68) for TT homozygotes with high folate intake (P interaction = 0.03).
  • In conclusion, folate intake seems to be inversely associated with promoter methylation in colorectal adenomas in case-case comparisons, and was positively associated with the occurrence of adenomas without promoter methylation in case-control comparisons, especially for TT homozygotes.
  • [MeSH-major] Adenoma / genetics. Colorectal Neoplasms / genetics. DNA Methylation. Folic Acid / administration & dosage. Methylenetetrahydrofolate Reductase (NADPH2) / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. DNA Repair / genetics. Female. Genes, Tumor Suppressor. Genetic Predisposition to Disease. Genotype. Humans. Logistic Models. Male. Middle Aged. Netherlands / epidemiology. Polymerase Chain Reaction. Promoter Regions, Genetic. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301267.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


52. Rescinito G, Zandrino F, Cittadini G Jr, Santacroce E, Giasotto V, Neumaier CE: Characterization of adrenal adenomas and metastases: correlation between unenhanced computed tomography and chemical shift magnetic resonance imaging. Acta Radiol; 2006 Feb;47(1):71-6
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of adrenal adenomas and metastases: correlation between unenhanced computed tomography and chemical shift magnetic resonance imaging.
  • PURPOSE: To evaluate the correlation of absolute attenuation values of unenhanced computed tomography (CT) with signal intensity (SI) quantitative analysis on chemical shift (CS) magnetic resonance (MR) imaging in differentiating adrenal adenomas from metastases.
  • MATERIAL AND METHODS: Forty-one adrenal masses (27 adenomas, 14 metastases) were studied with CS MR imaging and unenhanced CT.
  • RESULTS: The mean attenuation value of metastases was significantly greater than that of adenomas (< 0.0001).
  • On MR, the mean SI-i of adenomas was significantly greater than that of metastases (P < 0.0001) and no overlaps were evident.
  • The CS-r of malignant and benign lesions overlapped considerably, and five adenomas (all with indeterminate Hounsfield Unit values at CT) were misclassified as potentially malignant.
  • SI-i is the most reliable tool for differentiating adrenal adenomas from metastases, showing better accuracy than lesion-to-spleen CS-r, in particular for adenomas with indeterminate absolute attenuation values.
  • [MeSH-major] Adenoma / diagnosis. Adrenal Gland Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498936.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


53. Papagrigoriadis S: Transanal endoscopic micro-surgery (TEMS) for the management of large or sessile rectal adenomas: a review of the technique and indications. Int Semin Surg Oncol; 2006;3:13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic micro-surgery (TEMS) for the management of large or sessile rectal adenomas: a review of the technique and indications.
  • A number of techniques have been used to treat adenomas of the rectum.
  • The treatment of large adenomas which occupy a large surface of the rectal lumen or adenomas which are flat and grow in a "carpet-like" fashion is particularly challenging.
  • Gastroenterologists should be aware of the nature and indications of TEMS in order to advise and refer selected patients with rectal adenomas accordingly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol Hepatol. 2004 Jul;19(7):767-72 [15209623.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1376-80 [14571741.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1366-71 [15933798.001]
  • [Cites] Int J Impot Res. 2005 May-Jun;17(3):231-8 [15716980.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2015-24 [15657649.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1559-64 [16231283.001]
  • [Cites] Eur J Surg Oncol. 2005 Sep;31(7):735-42 [16180267.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1546-52 [16252312.001]
  • [Cites] Am J Surg. 1978 Aug;136(2):273-5 [686274.001]
  • [Cites] Endosc Surg Allied Technol. 1994 Oct;2(5):241-6 [7866754.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):207-10 [8689164.001]
  • [Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S79-84 [8831552.001]
  • [Cites] Arch Surg. 1998 Jun;133(6):595-8; discussion 598-9 [9637456.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Dec;10(6):372-8 [11147912.001]
  • [Cites] Int J Colorectal Dis. 2001 Nov;16(6):370-6 [11760898.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1174-82 [15449270.001]
  • [Cites] Surg Oncol. 2004 Aug-Nov;13(2-3):83-92 [15572090.001]
  • [Cites] Surg Endosc. 2005 Jun;19(6):751-6 [15868260.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):63-9; discussion 69-70 [1733375.001]
  • [Cites] Br J Surg. 1980 Sep;67(9):651-2 [7427065.001]
  • [Cites] Int J Colorectal Dis. 1995;10(2):112-6 [7636370.001]
  • [Cites] Surg Endosc. 1995 Oct;9(10):1106-12 [8553213.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):211-3 [8689165.001]
  • [Cites] Dis Colon Rectum. 1996 Oct;39(10):1116-21 [8831526.001]
  • [Cites] Chirurg. 1996 Feb;67(2):139-44 [8881210.001]
  • [Cites] Langenbecks Arch Surg. 1998 Oct;383(5):320-4 [9860223.001]
  • [Cites] Tumori. 1999 Jul-Aug;85(4):265-8 [10587029.001]
  • [Cites] World J Surg. 2001 Jul;25(7):870-5 [11572026.001]
  • [Cites] Dis Colon Rectum. 2002 May;45(5):601-4 [12004207.001]
  • [Cites] Int J Colorectal Dis. 2005 Jan;20(1):1-8 [15459771.001]
  • (PMID = 16674824.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1468413
  •  go-up   go-down


54. Iwata T, Yamada S, Mizusawa N, Golam HM, Sano T, Yoshimoto K: The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clin Endocrinol (Oxf); 2007 Apr;66(4):499-502
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas.
  • BACKGROUND: Recently, germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene located on 11q13 were identified in patients with pituitary adenoma predisposition.
  • To investigate the role of AIP in sporadic GH-secreting adenomas, we first analysed somatic mutations in 40 tumours.
  • Bi-allelic inactivation of AIP by a combination of germline mutation and loss of heterozygosity were confirmed in two pituitary adenomas.
  • Mutation analysis of the AIP gene in the 40 sporadic GH-secreting adenomas showed no mutations except for a missense mutation, suggesting that germline mutations in patients diagnosed with sporadic acromegaly or gigantism were rare.
  • CONCLUSION: Based on these results, we conclude that the loss of function of AIP contributes to IFS, but not for most Japanese sporadic GH-secreting adenomas.
  • [MeSH-major] Growth Hormone-Secreting Pituitary Adenoma / genetics. Mutation. Pituitary Neoplasms / genetics. Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17371465.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Proteins; 0 / aryl hydrocarbon receptor-interacting protein
  •  go-up   go-down


55. Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Montañana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabaté MI, Villa C, Popelier M, Salvatori R, Jennings J, Longás AF, Labarta Aizpún JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA, Beckers A: Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab; 2010 Nov;95(11):E373-83
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study.
  • CONTEXT: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases.
  • The clinical and therapeutic features of AIPmut-associated pituitary adenomas have not been studied comprehensively.
  • OBJECTIVE: The objective of the study was to assess clinical/therapeutic characteristics of AIPmut pituitary adenomas.
  • PATIENTS: Patients included 96 patients with germline AIPmut and pituitary adenomas and 232 matched AIPmut-negative acromegaly controls.
  • Somatotropinomas comprised 78.1% of the cohort; there were also prolactinomas (n = 13), nonsecreting adenomas (n = 7), and a TSH-secreting adenoma.
  • AIPmut somatotropinoma patients underwent more surgical interventions (P = 0.00069) and had lower decreases in GH (P = 0.00037) and IGF-I (P = 0.028) and less tumor shrinkage with somatostatin analogs (P < 0.00001) vs. controls.
  • CONCLUSIONS: AIPmut pituitary adenomas have clinical features that may negatively impact treatment efficacy.
  • Predisposition for aggressive disease in young patients, often in a familial setting, suggests that earlier diagnosis of AIPmut pituitary adenomas may have clinical utility.
  • [MeSH-major] Adenoma / genetics. Germ-Line Mutation. Pituitary Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20685857.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists
  •  go-up   go-down


56. Beuschlein F, Hancke K, Petrick M, Göbel H, Honegger J, Reincke M: Growth hormone receptor mRNA expression in non-functioning and somatotroph pituitary adenomas: implications for growth hormone substitution therapy? Exp Clin Endocrinol Diabetes; 2005 Apr;113(4):214-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth hormone receptor mRNA expression in non-functioning and somatotroph pituitary adenomas: implications for growth hormone substitution therapy?
  • The use of growth hormone (GH) in patients with GH deficiency induced by pituitary adenoma is widely accepted, but the safety of this mitogenic hormone, particularly in patients with residual tumor after neurosurgery, continues to be a concern.
  • Since the mitogenic potency of GH is dependent upon the presence of the GH receptor (GH-R) and the subsequent IGF-1/IGF receptor (IGF-1-R) system we investigated the expression of the members of the growth hormone cascade in endocrine inactive and GH-producing pituitary adenomas.
  • Tissue specimens of 18 clinically non-functioning pituitary adenomas and 6 GH-producing adenomas were collected following transsphenoidal surgery while normal cadaver pituitary glands served as controls.
  • Applying this sensitive RT-PCR based approach, GH-R expression was demonstrated in all normal pituitaries, most inactive adenomas (94%), and the majority of GH-producing adenomas (66%).
  • Both IGF-1 and IGF-1-R mRNA was detectable in the majority of inactive (72% and 77%, respectively) and somatotrophic adenomas (83% and 83%).
  • In summary, expression of members of the GH-IGF-1 cascade could be demonstrated in a substantial subset of patients with non-functioning and GH-producing pituitary adenomas.
  • [MeSH-major] Adenoma / genetics. Growth Hormone / analogs & derivatives. Growth Hormone / therapeutic use. Pituitary Neoplasms / genetics. RNA, Messenger / genetics. Receptors, Somatotropin / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15891957.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger; 0 / Receptors, Somatotropin; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


57. Husøy T, Knutsen HK, Løberg EM, Alexander J: Intestinal adenomas of Min-mice lack enterochromaffin cells, and have increased lysozyme production in non-Paneth cells. Anticancer Res; 2006 May-Jun;26(3A):1797-802

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal adenomas of Min-mice lack enterochromaffin cells, and have increased lysozyme production in non-Paneth cells.
  • BACKGROUND: Adenomatous polyposis coli (APC) are important in maintaining normal epithelial mucosa.
  • Paneth and enterochromaffin cells were studied in the intestine and intestinal adenomas from Min-mice with heterozygote and homozygote mutations in Apc, respectively.
  • MATERIALS AND METHODS: The presence of Paneth and enterochromaffin cells in normal intestine and adenomas from Min-mice was studied in sections stained with lysozyme/PAS and connexin32.
  • RESULTS: Min-mice intestinal adenomas had an increased number of lysozyme-producing Paneth/goblet and non-Paneth cells and a reduced number of enterochromaffin cells.
  • CONCLUSION: Altered cell differentiation in adenomas might be caused by different response to Wnt-signalling, while an increased number of enterochromaffin cells in the large intestine is rather an effect of a heterozygous Apc(Min) mutation.
  • [MeSH-major] Adenomatous Polyposis Coli / enzymology. Adenomatous Polyposis Coli / pathology. Enterochromaffin Cells / pathology. Muramidase / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16827109.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 3.2.1.17 / Muramidase
  •  go-up   go-down


58. Cuthbert RJ, Wilson JM, Scott N, Coletta PL, Hull MA: Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas. Eur J Cancer; 2009 Jun;45(9):1654-63
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas.
  • Therefore, we investigated CD74 gene expression in intestinal adenomas in Apc(Min/+) mice and humans.
  • CD74 mRNA (p31 and p41 splice variants) and immunoreactive CD74 protein levels were significantly lower in small intestinal and colonic Apc(Min/+) mouse adenomas compared with histologically normal mucosa.
  • Conversely, CD74 protein levels were actually increased in dysplastic epithelial cells in 47/55 (85%) human colorectal adenomas, with CD74 and MIF protein levels together predicting increasing dysplasia in individual adenomas (P=0.003).
  • Down-regulation of CD74 during Apc(Min/+) mouse intestinal tumorigenesis does not model increased CD74 expression at the early, benign stages of human colorectal carcinogenesis.
  • [MeSH-major] Adenoma / immunology. Antigens, Differentiation, B-Lymphocyte / metabolism. Antigens, Neoplasm / metabolism. Colorectal Neoplasms / immunology. Histocompatibility Antigens Class II / metabolism
  • [MeSH-minor] Animals. Down-Regulation / immunology. Gene Expression Regulation, Neoplastic / immunology. Humans. Intramolecular Oxidoreductases / metabolism. Macrophage Migration-Inhibitory Factors / metabolism. Mice. Mice, Inbred C57BL. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269807.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ G116/146; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Antigens, Neoplasm; 0 / Histocompatibility Antigens Class II; 0 / Macrophage Migration-Inhibitory Factors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Trans-Activators; 0 / invariant chain; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.2.1 / MIF protein, human
  •  go-up   go-down


59. Kodach LL, Bleuming SA, Musler AR, Peppelenbosch MP, Hommes DW, van den Brink GR, van Noesel CJ, Offerhaus GJ, Hardwick JC: The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer. Cancer; 2008 Jan 15;112(2):300-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer.
  • METHODS: The authors used a tissue microarray and immunohistochemistry of BMP receptors and signal transduction elements in adenomas and CRC specimens to elucidate the role of BMP signaling in CRC carcinogenesis.
  • RESULTS: The adenoma specimens expressed all 3 BMP receptors (BMPRs) (BMPR type 1a [BMPR1a], BMPR1b, and BMPR2) and expressed SMAD family member 4 (SMAD4); and 20 of 22 adenomas (90.9%) exhibited active BMP signaling, as determined by nuclear phosphorylated SMAD1,5,8 (pSMAD1,5,8) expression.
  • In contrast, pSMAD1,5,8 nuclear staining was present in 5 CRC specimens (22.7%) but was lost in 17 CRC specimens (77.3%; cancer vs adenoma; P< .0001).
  • The earliest loss of pSMAD1,5,8 nuclear staining was detected in regions of high-grade dysplasia/carcinoma in situ within adenomas.
  • CRCs showed frequent loss of BMPR2 (P< .0001) and SMAD4 (P< .01) compared with adenomas.
  • CONCLUSIONS: Taken together, the current results indicated that loss of BMP signaling correlates tightly with progression of adenomas to cancer and occurs relatively early during cancer progression.
  • [MeSH-major] Adenoma / etiology. Bone Morphogenetic Proteins / physiology. Colonic Neoplasms / etiology. Colorectal Neoplasms / etiology. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18008360.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Morphogenetic Proteins; 0 / Receptors, Transforming Growth Factor beta; 0 / SMAD4 protein, human; 0 / Smad4 Protein; EC 2.7.11.30 / Bone Morphogenetic Protein Receptors
  •  go-up   go-down


60. Rajakangas J, Misikangas M, Päivärinta E, Mutanen M: Chemoprevention by white currant is mediated by the reduction of nuclear beta-catenin and NF-kappaB levels in Min mice adenomas. Eur J Nutr; 2008 Apr;47(3):115-22
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention by white currant is mediated by the reduction of nuclear beta-catenin and NF-kappaB levels in Min mice adenomas.
  • METHODS: Multiple intestinal neoplasia (Min) mice were fed an AIN-93G based control diet or a diet containing 10% freeze dried white currant (Ribes x pallidum) for 10 weeks.
  • Cell signaling parameters were analysed from intestinal adenomas and surrounding mucosa by Western blotting and immunohistochemistry.
  • RESULTS: The white currant diet reduced the number of adenomas from 81 (min-max 47-114) to 51 (36-84) in the total small intestine of Min mice (P<0.02).
  • Most of the adenomas develop in the distal part of the small intestine, and in this area white currant reduced the number from 49 to 29.5 (P<0.01) and also the size of the adenomas from 0.88 mm to 0.70 mm (P<0.02).
  • In the colon white currant increased the number of adenomas (0.3+/-0.6 vs. 0.8+/-0.6, mean +/- SD, P<0.05), but did not affect the size.
  • White currant reduced nuclear beta-catenin and NF-kappaB protein levels in the adenomas (P<0.05 and P<0.02, respectively).
  • They were correlated with the size of adenomas (P<0.01).
  • [MeSH-major] Adenoma / prevention & control. Antineoplastic Agents, Phytogenic / pharmacology. Fruit / chemistry. Intestinal Mucosa / pathology. Intestinal Neoplasms / prevention & control. NF-kappa B / metabolism. beta Catenin / metabolism

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18389329.001).
  • [ISSN] 1436-6207
  • [Journal-full-title] European journal of nutrition
  • [ISO-abbreviation] Eur J Nutr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / NF-kappa B; 0 / beta Catenin
  •  go-up   go-down


61. van der Klaauw AA, Kars M, Biermasz NR, Roelfsema F, Dekkers OM, Corssmit EP, van Aken MO, Havekes B, Pereira AM, Pijl H, Smit JW, Romijn JA: Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clin Endocrinol (Oxf); 2008 Nov;69(5):775-84
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas.
  • OBJECTIVE: Quality of life (QoL) is impaired in patients treated for pituitary adenomas.
  • Therefore, we compared age- and gender-specific standard deviations (SD) scores (Z-scores) of QoL parameters in patients treated for pituitary adenomas.
  • PATIENTS AND METHODS: We determined Z-scores for health-related questionnaires [the Hospital Anxiety and Depression Scale (HADS), Multidimensional Fatigue Inventory (MFI)-20, Nottingham Health Profile (NHP), and Short Form Health Survey (SF-36)] in patients during long-term follow-up (13 +/- 8 years) after treatment for pituitary adenomas.
  • Z-scores were calculated by comparing the data for 403 patients with acromegaly (n = 118), Cushing's disease (CD; n = 58), prolactinoma (n = 128), and nonfunctioning macroadenoma (n = 99) with a control population (n = 440) for each subscale of the questionnaires and for total QoL score.
  • CONCLUSION: QoL is impaired in patients during long-term follow-up after treatment of pituitary adenomas.
  • Patients with pituitary adenomas should be informed of these persistent adverse effects of their disease on QoL to prevent inappropriate expectations with respect to the long-term results of treatment.
  • [MeSH-major] Adenoma / psychology. Pituitary Neoplasms / psychology. Quality of Life

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462264.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


62. Mao X, Hamoudi RA, Talbot IC, Baudis M: Allele-specific loss of heterozygosity in multiple colorectal adenomas: toward an integrated molecular cytogenetic map II. Cancer Genet Cytogenet; 2006 May;167(1):1-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allele-specific loss of heterozygosity in multiple colorectal adenomas: toward an integrated molecular cytogenetic map II.
  • Colorectal cancer (CRC) remains a significant public health challenge despite our increased understanding of the genetic defects underlying the pathogenesis of this common disease.
  • To identify additional loci likely involved in CRC and to test the hypothesis of allele-specific loss of heterozygosity (LOH) for the localization of CRC susceptibility genes, we initially conducted a genome-wide allelotyping analysis of 48 adenomas from a patient with familial adenomatous polyposis coli (FAP) and 63 adenomas from 7 patients with sporadic CRC using 79 fluorescently tagged oligonucleotide primers amplifying microsatellite loci covering the human genome.
  • Frequent allelic losses were identified at D17S802 (41%), D7S518 (40%), D18S53 (38%), D10S249 (32%), D2S391 (29%), D16S419 (27%), D15S1005 and D15S120 (24%), D9S274 and D11S1318 (23%), D14S65 (20%), D14S274 and D17S953 (19%), D19S424 (18%), D5S346 and D1S397 (15%), and D6S468 (13%) in multiple FAP adenomas.
  • Common LOH was also detected at D4S1584 (42%), D11S968 (31%), D17S953 (28%), D5S394, D9S286 and D10S249 (24%), D8S511 (23%), D13S158 (21%), D7S669 (20%), D18S58 (19%), D2S162 and D16S432 (16%), D2S206 (15%), D7S496 and D17S946 (14%), D6S292 (13%), D4S1586 and D8S283 (11%), and D1S2766 (10%) in multiple CRC adenomas.
  • In addition, allele-specific LOH at D5S346, D15S1005, and D15S120 was observed in multiple FAP adenomas (P < 0.01) and at D2S206 and D16S423 in multiple CRC (P < 0.05).
  • The combined results not only provide a comprehensive view of genetic losses in CRC, indicating the comparability of these different techniques, but they also reveal different novel loci in multiple adenomas from FAP and sporadic CRC patients, suggesting that they represent a distinct subtype of CRC in terms of allelic losses.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682279.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Al-Mefty O, Pravdenkova S, Gragnaniello C: A technical note on endonasal combined microscopic endoscopic with free head navigation technique of removal of pituitary adenomas. Neurosurg Rev; 2010 Apr;33(2):243-8; discussion 248-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A technical note on endonasal combined microscopic endoscopic with free head navigation technique of removal of pituitary adenomas.
  • The transsphenoidal approach is the approach of choice to treat most pituitary adenomas.
  • [MeSH-major] Adenoma / surgery. Microscopy. Nasal Cavity / surgery. Neuroendoscopy / methods. Neuronavigation. Pituitary Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20195677.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


64. Sainani A, Cabral S: Risperidone and pituitary adenomas. Aust N Z J Psychiatry; 2009 Feb;43(2):177
Hazardous Substances Data Bank. RISPERIDONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risperidone and pituitary adenomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19153927.001).
  • [ISSN] 1440-1614
  • [Journal-full-title] The Australian and New Zealand journal of psychiatry
  • [ISO-abbreviation] Aust N Z J Psychiatry
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antipsychotic Agents; L6UH7ZF8HC / Risperidone
  •  go-up   go-down


65. Mortini P, Barzaghi R, Losa M, Boari N, Giovanelli M: Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Neurosurgery; 2007 Jun;60(6):993-1002; discussion 1003-4
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients.
  • OBJECTIVE: Giant pituitary adenomas, defined as those measuring at least 4 cm in maximum diameter, are a therapeutic challenge.
  • We report our experience in a large, consecutive series of patients with giant adenomas.
  • METHODS: Between 1990 and 2004, 95 patients with a giant pituitary adenomas underwent surgery at our department.
  • Nonfunctioning pituitary adenoma was the most frequent type (n = 70; 73.7%), whereas hormone-secreting adenomas numbered only 25 (26.3%).
  • Radical tumor excision was obtained in 14 patients (14.7%).
  • Adjuvant medical and radiation therapies led to 74.5% (95% confidence interval, 62.7-86.4%) control of tumor growth at 5 years.
  • This was not different in patients with nonfunctioning pituitary adenomas compared with patients with hormone-secreting tumors.
  • In the subgroup of patients with nonfunctioning pituitary adenomas, radiation therapy had a protective role against tumor growth (P < 0.01).
  • CONCLUSION: Maximal surgical removal of giant adenomas through the transsphenoidal or transcranial approach, or both, aimed to relieve compression of the optic pathway and reduce tumor volume as much as possible, offers the best chances to control the tumor when followed with adjuvant medical and radiation therapies.
  • [MeSH-major] Adenoma / pathology. Adenoma / therapy. Neurosurgical Procedures / methods. Pituitary Neoplasms / pathology. Pituitary Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17538372.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Gondim JA, Schops M, de Almeida JP, de Albuquerque LA, Gomes E, Ferraz T, Barroso FA: Endoscopic endonasal transsphenoidal surgery: surgical results of 228 pituitary adenomas treated in a pituitary center. Pituitary; 2010;13(1):68-77
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic endonasal transsphenoidal surgery: surgical results of 228 pituitary adenomas treated in a pituitary center.
  • The aim of this study is to report the results of a consecutive series of patients undergoing pituitary surgery using a pure endoscopic endonasal approach and to evaluate the efficacy and safety of this procedure.
  • We reviewed the data of 228 consecutive patients who underwent endonasal transsphenoidal adenoma removal over an 10-year period.
  • Tumor removal rate, endocrinological outcomes, and complications were retrospectively assessed in 228 patients with pituitary adenomas who underwent 251 procedures between December 1998 and December 2007.
  • There were 93 nonfunctioning adenomas, 58 growth hormone-secreting, 41 prolactin-secreting, 28 adrenocorticotropin hormone secreting, 7 FSH-LH secreting and 1 thyroid-stimulating hormone-secreting adenomas.
  • The remission results for patients with nonfunctioning adenomas was 83% and for functioning adenomas were 76.3% (70.6% for GH hormone-secreting, 85.3% for prolactin hormone-secreting, 71.4% for ACTH hormone-secreting, 85.7% for FSH-LH hormone-secreting and 100% for TSH hormone-secreting), with no recurrence at the time of the last follow-up.
  • The endoscopic endonasal approach for resection of pituitary adenomas, provides acceptable results representing a safe alternative procedure to the microscopic approach.
  • This less invasive method, associated with a small number of complications, provides excellent tumor removal rates and represents an important tool for the achievement of good results in the pituitary surgery, mainly for the complete removal of large adenomas.
  • [MeSH-major] Adenoma / surgery. Endoscopy / methods. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697135.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pituitary Hormones
  •  go-up   go-down


67. Sarquis MS, Weber F, Shen L, Broelsch CE, Jhiang SM, Zedenius J, Frilling A, Eng C: High frequency of loss of heterozygosity in imprinted, compared with nonimprinted, genomic regions in follicular thyroid carcinomas and atypical adenomas. J Clin Endocrinol Metab; 2006 Jan;91(1):262-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of loss of heterozygosity in imprinted, compared with nonimprinted, genomic regions in follicular thyroid carcinomas and atypical adenomas.
  • Because imprinting silences one of the two alleles, resulting in functional haploinsufficiency, we hypothesized that loss of heterozygosity (LOH) at an imprinted locus may result in the deletion of the only functional copy of an imprinted tumor suppressor gene.
  • DESIGN: In total, thyroid tissue was obtained from 72 patients with thyroid neoplasias comprising 34 follicular thyroid carcinomas (FTCs) and 38 follicular adenomas.
  • We performed PCR-based LOH analysis of DNA from paired normal-tumor samples using 18 markers mapped to imprinted regions (IR) and 13 markers in nonimprinted regions (NIR).
  • RESULTS: Overall LOH frequencies for the IR markers were 26% for the adenomas and 38% for the carcinomas.
  • In the NIR, the overall LOH frequency was 23 and 26% for adenomas and FTCs, respectively.
  • The difference in LOH frequencies between IR and NIR was statistically significant only for the carcinomas (P = 0.001), although there was a similar trend for the atypical adenomas (ATY, P = 0.06).
  • The fact that the ATY trended toward differential IR/NIR LOH, similar to FTC, may suggest that loss of IR might be instrumental in the adenoma-carcinoma sequence in thyroid carcinogenesis and that ATY could be an important intermediate in this pathway.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Papillary, Follicular / genetics. Genomic Imprinting. Loss of Heterozygosity / physiology. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16249278.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P30CA16058
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


68. Chen WT, Khazaie K, Zhang G, Weissleder R, Tung CH: Detection of dysplastic intestinal adenomas using a fluorescent folate imaging probe. Mol Imaging; 2005 Jan-Mar;4(1):67-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of dysplastic intestinal adenomas using a fluorescent folate imaging probe.
  • APC(Delta468) mice injected with FFP showed fluorescent adenomas (target-to-background ratio, adenoma vs. adjacent normal mucosa, of 2.46 +/- 0.41), significantly higher (p < .001) than adenomas in animals injected with a non-folate-containing control probe.
  • Fluorescence-activated cell-sorting analysis revealed a 3-fold higher content of Mac1-positive cells in colonic adenomas compared with normal adjacent mucosa (6.8% vs. 2.2%), and confirmed the source of FFP-positive cells to be primarily an F4/80-positive macrophage subpopulation.
  • Taken together, these results indicate that probe potentially can be used to image dysplastic intestinal adenomas in vivo.
  • [MeSH-major] Adenoma / pathology. Flow Cytometry / methods. Folic Acid / analysis. Intestinal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15967128.001).
  • [ISSN] 1535-3508
  • [Journal-full-title] Molecular imaging
  • [ISO-abbreviation] Mol Imaging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 86355; United States / NCI NIH HHS / CA / R01 CA 104547-01A1; United States / NCI NIH HHS / CA / R01 CA 99385; United States / NCI NIH HHS / CA / R33 CA 88365
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Carrier Proteins; 0 / Fluorescent Dyes; 0 / Folate Receptors, GPI-Anchored; 0 / Macrophage-1 Antigen; 0 / Receptors, Cell Surface; 0 / monocyte-macrophage differentiation antigen; 935E97BOY8 / Folic Acid
  •  go-up   go-down


69. Liu W, Kunishio K, Matsumoto Y, Okada M, Nagao S: Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas. J Clin Neurosci; 2005 Sep;12(7):791-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas.
  • The aim of this study was to evaluate the relationship between expression of matrix metalloproteinase-2 (MMP-2) and cavernous sinus invasion in pituitary adenoma.
  • METHOD: Tissue samples from 54 pituitary adenomas were examined for expression of MMP-2 protein by immunohistochemistry.
  • The MMP-2 score of pituitary adenomas with cavernous sinus invasion (3.9 +/- 0.5) was significantly higher than those without invasion (2.3 +/- 0.2; P < 0.01).
  • There was no difference in MMP-2 score between macroadenomas (3.0 +/- 0.3) and microadenomas (2.1 +/- 0.4; P > 0.05), and also, no difference between the functioning adenomas (2.8 +/- 0.3) and non-functioning adenomas (2.8 +/- 0.3; P > 0.05).
  • MMP-2 mRNA expression was also intense in invasive pituitary adenomas and was significantly higher in invasive pituitary adenomas than those without invasion (68.2 +/- 15.3; 21.8 +/- 8.2; P < 0.05).
  • CONCLUSION: This study suggests that MMP-2 may be associated with aggressiveness and invasion in pituitary adenoma but is not related to tumor size or secretory function.
  • [MeSH-minor] Adolescent. Adult. Aged. Blotting, Northern / methods. Female. Humans. Immunohistochemistry / methods. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Invasiveness. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198918.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / RNA, Messenger; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


70. Winczyk K, Kunert-Radek J, Gruszka A, Radek M, Ławnicka H, Pawlikowski M: Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro. Neuro Endocrinol Lett; 2009 Mar;30(1):107-10
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.
  • It was shown that tumoral tissue, including the pituitary adenomas, posses PPARgamma receptors.
  • The aim of the present study was to examine the anti-tumour effect of RGZ on human pituitary adenomas in vitro.
  • MATERIALS AND METHODS: Cells of eight pituitary adenomas removed neurosurgically were used to our experiment.
  • RESULTS: On the basis of the pre-operative diagnosis the 6 clinically non-functioning adenomas (CNFPA), one case of acromegaly and one case of Cushing's disease were recognized.
  • THE MAIN FINDING: The obtained results indicate that RZG exerts a suppressive effect on the cell viability in non-functioning pituitary adenomas.
  • CONCLUSION: Our data suggest that rosiglitazone may be useful in the treatment of non-functioning pituitary adenomas, but its efficacy in Cushing's disease and acromegaly requires further study.
  • [MeSH-major] Adenoma / pathology. PPAR gamma / agonists. Pituitary Neoplasms / pathology. Thiazolidinediones / pharmacology
  • [MeSH-minor] Acromegaly / etiology. Acromegaly / pathology. Adrenocorticotropic Hormone / secretion. Adult. Aged. Cell Proliferation / drug effects. Cell Survival / drug effects. Drug Evaluation, Preclinical. Female. Human Growth Hormone / secretion. Humans. Hypoglycemic Agents / pharmacology. Male. Middle Aged. Pituitary ACTH Hypersecretion / etiology. Pituitary ACTH Hypersecretion / pathology. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. ROSIGLITAZONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19300395.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 0 / PPAR gamma; 0 / Thiazolidinediones; 05V02F2KDG / rosiglitazone; 12629-01-5 / Human Growth Hormone; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


71. de Graaf EJ, Doornebosch PG, Tetteroo GW, Geldof H, Hop WC: Transanal endoscopic microsurgery is feasible for adenomas throughout the entire rectum: a prospective study. Dis Colon Rectum; 2009 Jun;52(6):1107-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery is feasible for adenomas throughout the entire rectum: a prospective study.
  • INTRODUCTION: Transanal endoscopic microsurgery for rectal adenomas is safe and has low recurrence rates.
  • However, the feasibility of the procedure for all rectal adenomas is unclear.
  • METHODS: From 1996 to 2007, 353 consecutive rectal adenomas were evaluated according to a standard protocol.
  • Transanal endoscopic microsurgery was intended in all rectal adenomas.
  • Conversion rate correlated with the distance of the tumor (P = 0.007) and the operating surgeon's level of experience (P = 0.004).
  • All rectal adenomas were excised in one piece.
  • Rectal adenomas with incomplete margins were larger (P < 0.001) and were located more proximally (P < 0.001).
  • CONCLUSIONS: For nearly all rectal adenomas, transanal endoscopic microsurgery is safe, feasible, and has excellent results.
  • [MeSH-major] Adenoma / surgery. Microsurgery / methods. Proctoscopy / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581854.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Wang YY, Lin SY, Lai WA, Liu PH, Sheu WH: Association between adenomas of rectosigmoid colon and metabolic syndrome features in a Chinese population. J Gastroenterol Hepatol; 2005 Sep;20(9):1410-5
MedlinePlus Health Information. consumer health - Metabolic Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between adenomas of rectosigmoid colon and metabolic syndrome features in a Chinese population.
  • BACKGROUND AND AIMS: Metabolic syndrome (MS) consists of a cluster of diseases, including obesity, dyslipidemia, hyperglycemia and high blood pressure.
  • The purpose of the present study was to assess the association of MS with adenomas of the rectosigmoid colon, a well-established precancerous lesion.
  • Pathological findings were hyperplastic in 138 subjects, adenomas in 341, carcinomas in 10, and other benign lesions in 79.
  • In patients without polyps, the adjusted mean TG level and calculated BMI level were lower than those in patients with adenomas.
  • The odds ratio of adenomas in situ as compared to either a polyp-free state or the presence of hyperplastic polyps increased significantly with the number of MS diagnostic criteria the patient exhibited.
  • CONCLUSION: Our study shows that MS is associated with rectosigmoid adenomas in a Chinese population.
  • In patients with rectosigmoid polyps, the coexistence of MS may portend an increased risk of adenomas.
  • [MeSH-major] Adenoma / complications. Metabolic Syndrome X / complications. Rectal Neoplasms / complications. Sigmoid Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Blackwell Publishing Asia Pty Ltd.
  • (PMID = 16105129.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


73. Schulz AC, Bojarski C, Buhr HJ, Kroesen AJ: Occurrence of adenomas in the pouch and small intestine of FAP patients after proctocolectomy with ileoanal pouch construction. Int J Colorectal Dis; 2008 Apr;23(4):437-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of adenomas in the pouch and small intestine of FAP patients after proctocolectomy with ileoanal pouch construction.
  • PURPOSE: Proctocolectomy with ileoanal pouch construction is the standard therapy for patients with familial adenomatous polyposis coli (FAP) to prevent the genesis of colorectal carcinomas.
  • In our patient population, we observed the postoperative development of adenomas not only in the pouch but also in the remaining small intestine.
  • METHODS: We performed wireless capsule endoscopy (CE) in patients who developed postoperative pouch adenomas (PA) to record the simultaneous occurrence of small bowel adenomas and PA.
  • Eight PA patients (all with PA) also had adenomas in the small intestine diagnosed by CE.
  • CONCLUSIONS: Since jejunal and ileal adenomas occur in all patients with PA, we recommend regular follow-up examinations, which include pouch endoscopy at 3 months and annually after surgery in the presence of PA after proctocolectomy and pouch creation.
  • [MeSH-major] Adenoma / epidemiology. Adenomatous Polyposis Coli / surgery. Colonic Pouches / adverse effects. Intestine, Small / pathology. Proctocolectomy, Restorative / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18193239.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


74. Buso AG, Rocha HL, Diogo DM, Diogo PM, Diogo-Filho A: Seroprevalence of Helicobacter pylori in patients with colon adenomas in a Brazilian university hospital. Arq Gastroenterol; 2009 Apr-Jun;46(2):97-101
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seroprevalence of Helicobacter pylori in patients with colon adenomas in a Brazilian university hospital.
  • CONTEXT: The association between Helicobacter pylori infection and colon neoplasia has been the subject of recent investigations which have produced controversial results.
  • OBJECTIVE: To evaluate the prevalence of H. pylori infection in patients with colonic adenomas and also in patients whose colonoscopy exams were normal.
  • METHODS: After colonoscopy, the individuals were distributed into two groups: patients with colon adenomas (cases) and patients whose colons were normal (controls).
  • The prevalence of H. pylori in cases and controls according to gender, histological type and location of the colon lesions showed a significant difference only among women (P = 0.03), among patients with tubular adenomas (P = 0.03), and in those with distal adenomas (P = 0.038).
  • CONCLUSION: There is a positive association between H. pylori infection and colonic adenomas.
  • This association is more evident in women, especially for tubular adenomas and distal colonic location.
  • [MeSH-major] Adenoma / microbiology. Colonic Neoplasms / microbiology. Helicobacter Infections / epidemiology. Helicobacter pylori

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19578608.001).
  • [ISSN] 1678-4219
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Biomarkers; 0 / Immunoglobulin G
  •  go-up   go-down


75. Socas L, Zumbado M, Pérez-Luzardo O, Ramos A, Pérez C, Hernández JR, Boada LD: Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med; 2005 May;39(5):e27
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature.
  • The misuse of these drugs is associated with serious adverse effects to the liver, including cellular adenomas and adenocarcinomas.
  • We report two very different cases of adult male bodybuilders who developed hepatocellular adenomas following AAS abuse.
  • The second patient was admitted to our hospital with acute renal failure and ultrasound (US) studies showed mild hepatomegaly with several very close hyperecogenic nodules in liver, concordant with adenomas at first diagnosis.
  • The cases presented here are rare but may well be suggestive of the natural course of AAS induced hepatocellular adenomas.
  • [MeSH-major] Adenoma, Liver Cell / chemically induced. Anabolic Agents / adverse effects. Liver Neoplasms / chemically induced. Methenolone / analogs & derivatives. Nandrolone / analogs & derivatives. Substance-Related Disorders / complications. Testosterone / analogs & derivatives. Testosterone Propionate / analogs & derivatives. Weight Lifting

  • MedlinePlus Health Information. consumer health - Anabolic Steroids.
  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • Hazardous Substances Data Bank. STANOZOLOL .
  • Hazardous Substances Data Bank. OXYMETHOLONE .
  • Hazardous Substances Data Bank. NANDROLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849280.001).
  • [ISSN] 1473-0480
  • [Journal-full-title] British journal of sports medicine
  • [ISO-abbreviation] Br J Sports Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anabolic Agents; 0SPD480WFH / methenolone enanthate; 3XMK78S47O / Testosterone; 4R1VB9P8V3 / Stanozolol; 5H7I2IP58X / boldenone; 6PG9VR430D / Nandrolone; 7Z6522T8N9 / testosterone enanthate; 8GN84GWX51 / testosterone 17-phenylpropionate; 9062ZT8Q5C / Methenolone; H45187T098 / nandrolone decanoate; L76T0ZCA8K / Oxymetholone; WI93Z9138A / Testosterone Propionate
  • [Number-of-references] 17
  • [Other-IDs] NLM/ PMC1725213
  •  go-up   go-down


76. Chacko G: Non-functional pituitary adenomas. Neurol India; 2010 May-Jun;58(3):341-2
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-functional pituitary adenomas.
  • [MeSH-major] Adenoma. Pituitary Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644259.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] India
  •  go-up   go-down


77. Kleinschmidt-DeMasters BK: Subtyping does matter in pituitary adenomas. Acta Neuropathol; 2006 Jan;111(1):84-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtyping does matter in pituitary adenomas.
  • [MeSH-minor] Adrenocorticotropic Hormone / analysis. Biomarkers / analysis. Homeodomain Proteins / analysis. Human Growth Hormone / analysis. Humans. Immunohistochemistry. Keratins / analysis. Ki-67 Antigen / analysis. Microscopy, Electron. Prolactin / analysis. Receptors, Cytoplasmic and Nuclear / analysis. Steroidogenic Factor 1. Thyrotropin / analysis. Transcription Factor Pit-1 / analysis. Transcription Factors / analysis. Tumor Suppressor Protein p53 / analysis. World Health Organization

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Acta Neuropathol. 2006 Jan;111(1):1-7 [16328527.001]
  • (PMID = 16328517.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / Homeodomain Proteins; 0 / Ki-67 Antigen; 0 / POU1F1 protein, human; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Steroidogenic Factor 1; 0 / TP53 protein, human; 0 / Transcription Factor Pit-1; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; 12629-01-5 / Human Growth Hormone; 68238-35-7 / Keratins; 9002-60-2 / Adrenocorticotropic Hormone; 9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin
  •  go-up   go-down


78. V Schönfeld J, Hinzmann S: Missed colonic adenomas in routine primary care endoscopy: a prospective tandem colonoscopy study. Z Gastroenterol; 2010 Oct;48(10):1207-10
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Missed colonic adenomas in routine primary care endoscopy: a prospective tandem colonoscopy study.
  • Colonoscopy is the gold standard in the diagnosis of colorectal neoplasia.
  • Several lines of independent evidence, however, suggest that a significant number of small adenomas and also some advanced lesions are missed even by experienced endoscopists.
  • A total of 98 neoplastic lesions were identified in 34 patients at the index colonoscopy, an additional 53 adenomas were removed at the second colonoscopy, 33 of them smaller than 5 mm.
  • 25 out of 53 missed adenomas were identified between the coecum and the right colonic flexure.
  • 12 of the additional lesions were considered significant lesions (larger than 10 mm or tubulovillous adenoma), nine of these were located between the coecum and the right colonic flexure.
  • In 24 patients repeat colonoscopy detected adenomas not described in the original report.
  • About one-third of adenomas were missed in 40 routine colonoscopies, most of them only small and therefore probably of little clinical significance.
  • Adenomas in the right colon seem to be a particular problem.
  • [MeSH-major] Adenoma / pathology. Adenoma / surgery. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Colonoscopy / statistics & numerical data. Medical Errors / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 20886425.001).
  • [ISSN] 1439-7803
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


79. Figueiredo JC, Levine AJ, Grau MV, Barry EL, Ueland PM, Ahnen DJ, Byers T, Bresalier RS, Summers RW, Bond J, McKeown-Eyssen GE, Sandler RS, Haile RW, Baron JA: Colorectal adenomas in a randomized folate trial: the role of baseline dietary and circulating folate levels. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2625-31
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal adenomas in a randomized folate trial: the role of baseline dietary and circulating folate levels.
  • The Aspirin/Folate Polyp Prevention Study is a randomized, placebo-controlled trial of aspirin use and folic acid supplementation and incidence of colorectal adenomas in individuals with a history of these lesions.
  • The trial showed that folic acid supplementation does not prevent the occurrence of new adenomas and may increase risk.
  • There was little evidence that baseline dietary and total folate intake, and plasma and RBC folate modified the association between folic acid treatment and risk of any adenomas or advanced lesions.
  • However, there was a protective association of the highest tertile of dietary and total intake as well as circulating folate with risk of any adenomas among those in the placebo group but no association among individuals in the folic acid group.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2008 Apr;54(4):665-72 [18281423.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):189-93 [16492904.001]
  • [Cites] Gut. 2006 Oct;55(10):1387-9 [16966698.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3191-9 [10866310.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5434-40 [11034085.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):715-9 [11401925.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):227-34 [11895870.001]
  • [Cites] J Nutr. 2002 Aug;132(8 Suppl):2350S-2355S [12163691.001]
  • [Cites] J Nutr. 2002 Aug;132(8 Suppl):2413S-2418S [12163703.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):850-61 [12415255.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] J Nutr. 2003 Nov;133(11 Suppl 1):3731S-3739S [14608107.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):511-9 [15066913.001]
  • [Cites] Nutr Rev. 2004 Jun;62(6 Pt 2):S35-9 [15298446.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):875-84 [8492316.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov;4(7):709-14 [8672986.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):487-94 [8827351.001]
  • [Cites] Am J Clin Nutr. 1997 Jun;65(6):1790-5 [9174474.001]
  • [Cites] Methods Enzymol. 1997;281:43-53 [9250965.001]
  • [Cites] Am J Surg. 1997 Oct;174(4):425-30 [9337168.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):57-62 [9428784.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13217-20 [9789068.001]
  • [Cites] J Nutr. 1998 Nov;128(11):1956-60 [9808649.001]
  • [Cites] Am J Clin Nutr. 2004 Nov;80(5):1123-8 [15531657.001]
  • [Cites] J Am Coll Nutr. 2005 Aug;24(4):266-74 [16093404.001]
  • [Cites] J Nutr. 2006 Jan;136(1):189-94 [16365081.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):15-25 [16391368.001]
  • [Cites] Am J Epidemiol. 2006 Jan 15;163(2):108-15 [16339055.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2408-9 [17551134.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1325-9 [17626997.001]
  • [Cites] Am J Clin Nutr. 2007 Aug;86(2):271-3 [17684194.001]
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):718-27 [17823438.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2128-35 [17932361.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):243-50 [16453285.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1440-6 [16615116.001]
  • (PMID = 18843003.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U54 CA100971-05S1; United States / NCI NIH HHS / CA / U54-CA-100971; United States / NCI NIH HHS / CA / R01-CA-059005; United States / NCI NIH HHS / CA / R01 CA059005-14; United States / NCI NIH HHS / CA / CA100971-05S1; United States / NCI NIH HHS / CA / U54 CA100971-05; United States / NCI NIH HHS / CA / CA100971-05; United States / NCI NIH HHS / CA / U54 CA100971; United States / NCI NIH HHS / CA / CA059005-14; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CA / R01 CA059005; United States / NCRR NIH HHS / RR / UL1 RR024979
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Placebos; 935E97BOY8 / Folic Acid; R16CO5Y76E / Aspirin
  • [Other-IDs] NLM/ NIHMS64547; NLM/ PMC2597215
  •  go-up   go-down


80. Jagannathan J, Yen CP, Pouratian N, Laws ER, Sheehan JP: Stereotactic radiosurgery for pituitary adenomas: a comprehensive review of indications, techniques and long-term results using the Gamma Knife. J Neurooncol; 2009 May;92(3):345-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for pituitary adenomas: a comprehensive review of indications, techniques and long-term results using the Gamma Knife.
  • OBJECT: This study reviews the long-term clinical results of stereotactic radiosurgery in the treatment of pituitary adenoma patients.
  • METHODS: We reviewed the outcomes of 298 patients who underwent Gamma Knife radiosurgery for recurrent or residual pituitary adenomas.
  • The overall rate of volume reduction following stereotactic radiosurgery is 85% for non-secretory adenomas that are followed for more than 1-year.
  • The rates of hormonal normalization in patients with hypersecretory adenomas can vary considerably, and tends to be higher in patients with Cushing's Disease and acromegaly (remission rate of approximately 53% and 54%, respectively) when compared with patients who have prolactinomas (24% remission) and Nelson's syndrome (29%) remission.
  • Advances in dose delivery and modulation of adenoma cells at the time of radiosurgery may further improve results.
  • CONCLUSIONS: Although the effectiveness of radiosurgery varies considerably depending on the adenoma histopathology, volume, and radiation dose, most studies indicate that radiosurgery when combined with microsurgery is effective in controlling pituitary adenoma growth and hormone hypersecretion.
  • Long-term follow-up is essential to determine the rate of endocrinopathy, visual dysfunction, hormonal recurrence, and adenoma volume control.
  • [MeSH-major] Adenoma / surgery. Pituitary Neoplasms / surgery. Radiosurgery / methods

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19357961.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 100
  •  go-up   go-down


81. Pawlikowski M, Winczyk K: Immunohistochemical detection of prothymosin alpha in pituitary adenomas--a new marker of tumor recurrence? Folia Histochem Cytobiol; 2009;47(4):559-62
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of prothymosin alpha in pituitary adenomas--a new marker of tumor recurrence?
  • Forty pituitary adenomas were immunostained with an antibody raised against the C-terminal fragment (101-109) of human prothymosin alpha (PT alpha).
  • The strong positive immunostaining was found in the subpopulation of cell nuclei and intratumoral vessel walls, while the cytoplasm of adenoma cells was slightly immunopositive.
  • The significantly higher percentage of PT alpha-positive cell nuclei was found in recurrent pituitary adenomas as compared with primary tumors.
  • Gonadotropinomas were characterized by higher nuclear PT alpha expression in comparison to other pituitary adenomas, which is probably linked with the high recurrence rate of these tumors.
  • It is suggested that PT alpha immunostaining may be helpful in predicting the pituitary tumor recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20430720.001).
  • [ISSN] 1897-5631
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Protein Precursors; 0 / prothymosin alpha; 61512-21-8 / Thymosin
  •  go-up   go-down


82. Waye JD, Heigh RI, Fleischer DE, Leighton JA, Gurudu S, Aldrich LB, Li J, Ramrakhiani S, Edmundowicz SA, Early DS, Jonnalagadda S, Bresalier RS, Kessler WR, Rex DK: A retrograde-viewing device improves detection of adenomas in the colon: a prospective efficacy evaluation (with videos). Gastrointest Endosc; 2010 Mar;71(3):551-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrograde-viewing device improves detection of adenomas in the colon: a prospective efficacy evaluation (with videos).
  • BACKGROUND: Colonoscopy may fail to detect neoplasia located on the proximal sides of haustral folds and flexures.
  • The Third Eye Retroscope (TER) provides a simultaneous retrograde view that complements the forward view of a standard colonoscope.
  • OBJECTIVE: To evaluate the added benefit for polyp detection during colonoscopy of a retrograde-viewing device.
  • MAIN OUTCOME MEASUREMENTS: The number and sizes of lesions (adenomas and all polyps) detected with the standard colonoscope and the number and sizes of lesions found only because they were first detected with the TER.
  • RESULTS: In the 249 subjects, 257 polyps (including 136 adenomas) were identified with the colonoscope alone.
  • The TER allowed detection of 34 additional polyps (a 13.2% increase; P < .0001) including 15 additional adenomas (an 11.0% increase; P < .0001).
  • For lesions 6 mm or larger, the additional detection rates with the TER for all polyps and for adenomas were 18.2% and 25.0%, respectively.
  • For lesions 10 mm or larger, the additional detection rates with the TER for all polyps and for adenomas were 30.8% and 33.3%, respectively.
  • For all polyps and for adenomas, the additional detection rates for the TER were 9.7%/4.1% in the left colon (the splenic flexure to the rectum) and 16.5%/14.9% in the right colon (the cecum to the transverse colon), respectively.
  • CONCLUSIONS: A retrograde-viewing device revealed areas that were hidden from the forward-viewing colonoscope and allowed detection of 13.2% additional polyps, including 11.0% additional adenomas.
  • Additional detection rates with the TER for adenomas 6 mm or larger and 10 mm or larger were 25.0% and 33.3%, respectively. ( CLINICAL TRIAL REGISTRATION NUMBER: NCT00657371.).
  • [MeSH-major] Adenoma / diagnosis. Colonic Neoplasms / diagnosis. Colonoscopes. Colonoscopy

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
  • [CommentIn] Gastrointest Endosc. 2010 Mar;71(3):557-9 [20189514.001]
  • [CommentIn] Gastrointest Endosc. 2011 Jan;73(1):190; author reply 193-4 [21184890.001]
  • [CommentIn] Gastrointest Endosc. 2011 Mar;73(3):637; author reply 637-8 [21353861.001]
  • (PMID = 20018280.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00657371
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Weinreb I, Simpson RH, Skálová A, Perez-Ordoñez B, Dardick I, Chetty R, Hunt JL: Ductal adenomas of salivary gland showing features of striated duct differentiation ('striated duct adenoma'): a report of six cases. Histopathology; 2010 Nov;57(5):707-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal adenomas of salivary gland showing features of striated duct differentiation ('striated duct adenoma'): a report of six cases.
  • AIMS: To describe a salivary adenoma composed largely of unilayered ducts resembling striated ducts, and to differentiate it from similar adenomas, including canalicular and intercalated duct adenoma.
  • METHODS AND RESULTS: Six unilayered ductal adenomas were identified in parotid (four) and palate (two).
  • The typical epithelial 'beading' pattern with abundant stroma of canalicular adenoma was absent.
  • CONCLUSIONS: Striated duct adenomas are unilayered ductal tumours that recapitulate normal striated ducts.
  • [MeSH-major] Adenoma / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Limited.
  • (PMID = 21054495.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


84. Kawamata T, Kubo O, Hori T: Surgical removal of growth hormone-secreting pituitary adenomas with intensive microsurgical pseudocapsule resection results in complete remission of acromegaly. Neurosurg Rev; 2005 Jul;28(3):201-8
MedlinePlus Health Information. consumer health - Brain Aneurysm.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical removal of growth hormone-secreting pituitary adenomas with intensive microsurgical pseudocapsule resection results in complete remission of acromegaly.
  • Although some investigators recommended surgical removal of the borders between pituitary adenoma and the surrounding normal pituitary gland, there is so far little documentation of how intensive dissection of the border zone affects the actual clinical remission rate of pituitary adenomas.
  • We investigated the precise histological characteristics of the boundary, using surgical specimens from patients who underwent intensive resection of "microsurgical pseudocapsule" of growth hormone (GH)-secreting pituitary adenomas.
  • Histologically, most adenomas were in direct contact with normal pituitary gland that formed an increased fibrous component facing the adenoma, without a true histological pseudocapsule.
  • It was impossible to dissect the tumor at exactly the tumor--normal pituitary interface for the whole extent of the pituitary adenoma during surgery, and complete removal of the tumor inevitably included a portion of normal tissue (microsurgical pseudocapsule).
  • The present results suggested that intensive resection of the microsurgical pseudocapsule is essential to accomplish histological and endocrinological total resection of the GH-secreting pituitary adenomas for remission of acromegaly.

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15765245.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


85. Widhalm G, Wolfsberger S, Preusser M, Fischer I, Woehrer A, Wunderer J, Hainfellner JA, Knosp E: Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. J Neurosurg; 2009 Sep;111(3):563-71
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression.
  • OBJECT: In residual nonfunctioning pituitary adenomas, reliable prognostic parameters indicating probability of tumor progression are needed.
  • The aim in the present study was to analyze the clinical usefulness of MIB-1 LI for prognosis of tumor progression.
  • METHODS: The authors studied a cohort of 92 patients with nonfunctioning pituitary adenomas.
  • Based on sequential postoperative MR images, patients were classified as tumor free (51 patients) or as harboring residual tumor (41 individuals).
  • The residual tumor group was further subdivided in groups with stable residual tumors (14 patients) or progressive residual tumors (27 patients).
  • The MIB-1 LI was assessed in tumor specimens obtained in all patients, and statistical comparisons of MIB-1 LI of the various subgroups were performed.
  • RESULTS: The authors found no significant difference of MIB-1 LI in the residual tumor group compared with the tumor-free group.
  • However, MIB-1 LI was significantly higher in the progressive residual tumor group, compared with the stable residual tumor group.
  • Additionally, the time period to second surgery was significantly shorter in residual adenomas showing an MIB-1 LI>3%.
  • CONCLUSIONS: The data indicate that MIB-1 LI in nonfunctioning pituitary adenomas is a clinically useful prognostic parameter indicating probability of progression of postoperative tumor remnants.
  • The MIB-1 LI may be helpful in decisions of postoperative disease management (for example, frequency of radiographic intervals, planning for reoperation, radiotherapy, and/or radiosurgery).
  • [MeSH-major] Adenoma / diagnosis. Ki-67 Antigen / analysis. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm, Residual / diagnosis. Postoperative Period. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18991501.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


86. Hanson JM, Mol JA, Meij BP: Expression of leukemia inhibitory factor and leukemia inhibitory factor receptor in the canine pituitary gland and corticotrope adenomas. Domest Anim Endocrinol; 2010 May;38(4):260-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of leukemia inhibitory factor and leukemia inhibitory factor receptor in the canine pituitary gland and corticotrope adenomas.
  • The aim of this study was to investigate the expression of LIF and its receptor (LIFR) in the canine pituitary gland and in corticotrope adenomas, and to perform a mutation analysis of LIFR.
  • Using immunohistochemistry, immunofluorescence, and quantitative expression analysis, LIF and LIFR expression were studied in pituitary glands of control dogs and in specimens of corticotrope adenoma tissue collected through hypophysectomy in dogs with pituitary-dependent hypercortisolism (PDH, Cushing's disease).
  • In the control pituitary tissues and corticotrope adenomas, there was a low magnitude of LIF expression.
  • Cytoplasmatic immunoreactivity of LIFR was preserved in corticotrope adenomas and adjacent nontumorous cells of pars intermedia.
  • These data show that LIFR is highly co-expressed with adrenocorticotropic hormone (ACTH) and alpha-melanocyte-stimulating hormone (alpha-MSH) in the canine pituitary gland and in corticotrope adenomas.
  • Nuclear immunoreactivity for LIFR in nontumorous cells of the pars distalis may indicate the presence of a corticotrope adenoma.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / veterinary. Dog Diseases / metabolism. Leukemia Inhibitory Factor / analysis. Pituitary Gland / chemistry. Pituitary Neoplasms / veterinary. Receptors, OSM-LIF / analysis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Cosyntropin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Inc. All rights reserved.
  • (PMID = 20036483.001).
  • [ISSN] 1879-0054
  • [Journal-full-title] Domestic animal endocrinology
  • [ISO-abbreviation] Domest. Anim. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Leukemia Inhibitory Factor; 0 / Receptors, OSM-LIF; 16960-16-0 / Cosyntropin; 581-05-5 / alpha-MSH
  •  go-up   go-down


87. Xue-Fei S, Yong-Fei W, Shi-Qi L, Jing-Song W, Yao Z, Ying M, Liang-Fu Z: Microsurgical treatment for giant and irregular pituitary adenomas in a series of 54 consecutive patients. Br J Neurosurg; 2008 Oct;22(5):636-48
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsurgical treatment for giant and irregular pituitary adenomas in a series of 54 consecutive patients.
  • The aim of this investigation was to evaluate the clinical significance of the various optional surgical approaches for giant and irregular pituitary adenomas and to summarize the optimal surgical protocols for the adenomas in terms of different growth morphologies.
  • Fifty-four cases with giant and irregular pituitary adenomas were treated by studying their clinical features and image examinations, designing the specific surgical protocols, and choosing the optimal approaches according to the various growth morphologies.
  • [MeSH-major] Adenoma / surgery. Microsurgery / methods. Neuroendoscopy / methods. Pituitary Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19016116.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Osamura RY, Egashira N, Kajiya H, Takei M, Tobita M, Miyakoshi T, Inomoto C, Takekoshi S, Teramoto A: Pathology, pathogenesis and therapy of growth hormone (GH)-producing pituitary adenomas: technical advances in histochemistry and their contribution. Acta Histochem Cytochem; 2009 Aug 29;42(4):95-104

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology, pathogenesis and therapy of growth hormone (GH)-producing pituitary adenomas: technical advances in histochemistry and their contribution.
  • Growth hormone (GH)-producing adenomas (GHomas) are one of the most frequently-occurring pituitary adenomas.
  • Differentiation of hormone-producing cells in the pituitary gland is regulated by transcription factors and co-factors.
  • Aberrant expression of transcription factors such as Pit-1 results in translineage expression of GH in adrenocorticotropic hormone-producing adenomas (ACTHomas).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endocrinol. 2002 Mar;172(3):477-87 [11874696.001]
  • [Cites] Brain Tumor Pathol. 2002;19(2):63-7 [12622135.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4239-45 [12970293.001]
  • [Cites] Gene. 2003 Nov 13;319:1-19 [14597167.001]
  • [Cites] J Neurochem. 2004 Jun;89(5):1057-91 [15147500.001]
  • [Cites] Pituitary. 1999 May;1(3-4):269-71 [11081207.001]
  • [Cites] Hum Pathol. 2000 Jul;31(7):789-94 [10923914.001]
  • [Cites] Neth J Med. 2007 Jul-Aug;65(7):263-6 [17656813.001]
  • [Cites] Mol Endocrinol. 2006 Nov;20(11):2796-805 [16840539.001]
  • [Cites] Front Horm Res. 2006;35:129-34 [16809928.001]
  • [Cites] Cell Tissue Res. 2005 Nov;322(2):269-77 [16133148.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2731-7 [9253362.001]
  • [Cites] Endocr J. 1993 Feb;40(1):133-9 [7951487.001]
  • [Cites] Mol Cell Biol. 1993 Apr;13(4):2342-53 [8455616.001]
  • [Cites] Cell. 1992 Aug 21;70(4):527-30 [1505020.001]
  • [Cites] Pathol Res Pract. 1988 Sep;183(5):569-71 [2467267.001]
  • [Cites] Cell. 1988 Mar 11;52(5):685-95 [3345568.001]
  • [Cites] Cell. 1987 Jul 17;50(2):267-75 [3594572.001]
  • [Cites] J Histochem Cytochem. 1970 Jan;18(1):9-20 [4190174.001]
  • [Cites] Endocr Pathol. 2008 Winter;19(4):261-73 [19034702.001]
  • [Cites] Histochem Cell Biol. 2008 Sep;130(3):495-507 [18688636.001]
  • [Cites] Acta Histochem Cytochem. 2008 Jun 27;41(3):47-57 [18636109.001]
  • [Cites] Endocr Pathol. 2007 Winter;18(4):208-16 [17987403.001]
  • [Cites] Brain Tumor Pathol. 2006 Apr;23(1):1-5 [18095112.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):11-7 [11796836.001]
  • [Cites] Front Horm Res. 2004;32:20-33 [15281338.001]
  • [Cites] Cell. 2001 Mar 23;104(6):849-59 [11290323.001]
  • [Cites] Hum Mol Genet. 2001 May 15;10(11):1141-53 [11371507.001]
  • (PMID = 19759870.001).
  • [ISSN] 0044-5991
  • [Journal-full-title] Acta histochemica et cytochemica
  • [ISO-abbreviation] Acta Histochem Cytochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2742723
  • [Keywords] NOTNLM ; cell lineage / functional differentiation / pituitary adenoma / pituitary hormones / transcription factor
  •  go-up   go-down


89. Reddy KA, Trimurthy Rao A, Krishna R, Manjula Y, Sambasiva Rao M, Srinivasulu K: A rare case of bilateral basal cell adenomas in the parotid glands. Indian J Surg; 2008 Feb;70(1):32-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of bilateral basal cell adenomas in the parotid glands.
  • Based on clinical features a provisional diagnosis of bilateral pleomorphic adenomas was made.
  • Bilateral superficial conservative parotidectomy with facial nerve preservation revealed bilateral encapsulated and lobulated tumors which on histopathological examination revealed bilateral basal cell adenomas in both parotid glands.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laryngol Otol. 2000 Jan;114(1):83-5 [10789423.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2000 Sep-Oct;62(5):278-81 [10965265.001]
  • (PMID = 23133013.001).
  • [ISSN] 0972-2068
  • [Journal-full-title] The Indian journal of surgery
  • [ISO-abbreviation] Indian J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3452595
  • [Keywords] NOTNLM ; Basal cell adenoma / Bilateral parotid tumors / Parotid tumors
  •  go-up   go-down


90. Gao F, Liao C, Liu L, Tan A, Cao Y, Mo Z: The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials. Colorectal Dis; 2009 Nov;11(9):893-901
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials.
  • PURPOSE: Colorectal adenomas are precursors of most colorectal cancers and are important targets for chemoprevention.
  • However, the role of aspirin in preventing recurrence of adenomas is controversial.
  • We performed a systematic review and meta-analysis to evaluate the effect of aspirin in preventing the recurrence of colorectal adenoma.
  • Main outcome measures were the recurrence of any new adenoma and advanced adenoma.
  • We found that the relative risks of any adenoma (when compared with the placebo group) were 0.859 in the high dose of aspirin groups (95% confidence interval (CI), 0.756-0.976, P = 0.019), 0.826 in the low dose of aspirin groups (95% CI 0.706-0.965, P = 0.016) and 0.836 in the both aspirin combined groups (95% CI 0.746-0.937, P = 0.002).
  • For the recurrence of advanced adenoma, the relative risk (when compared with the placebo group) was 0.655 (95% CI 0.513-0.837, P = 0.001) in the aspirin groups without considering the dose.
  • CONCLUSION: This meta-analysis suggests that aspirin prevents recurrent colorectal adenomas among patients with a history of colorectal adenomas.
  • [MeSH-major] Adenoma / drug therapy. Aspirin / therapeutic use. Colorectal Neoplasms / drug therapy. Cyclooxygenase Inhibitors / therapeutic use. Neoplasm Recurrence, Local / prevention & control

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055515.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; R16CO5Y76E / Aspirin
  • [Number-of-references] 53
  •  go-up   go-down


91. Swelam W, Ida-Yonemochi H, Maruyama S, Ohshiro K, Cheng J, Saku T: Vascular endothelial growth factor in salivary pleomorphic adenomas: one of the reasons for their poorly vascularized stroma. Virchows Arch; 2005 Jun;446(6):653-62
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor in salivary pleomorphic adenomas: one of the reasons for their poorly vascularized stroma.
  • To better understand the poorly vascularized background of the stroma of pleomorphic adenomas, we attempted to determine the expression of molecules related to blood vessels and hypoxic conditions in pleomorphic adenoma.
  • Surgical specimens and tumor cells in primary culture of salivary pleomorphic adenomas were used for immunohistochemistry for CD31, vascular endothelial growth factor (VEGF) and its receptors Flk-1 and Flt-1, as well as for hypoxia markers, such as hypoxia-inducible factor-1alpha (HIF-1alpha) and lactate dehydrogenase-1 (LDH).
  • In addition to co-immunolocalization with CD31+ vascular endothelial cells, VEGF and its receptors were demonstrated in normal duct epithelial and myoepithelial cells as well as in tumor cells in ductal structures and in myxochondroid stromata.
  • Immunofluorescence signals for VEGF and others were confirmed in pleomorphic adenoma cells in culture.
  • RT-PCR results showed that there were at least four splicing modes of the VEGF gene, among which VEGF(121) was most enhanced, and higher HIF-1alpha levels in pleomorphic adenomas.
  • The results suggest that pleomorphic adenoma cells produce VEGF in several functional forms for their own proliferation or differentiation, and that the VEGF expression is controlled by hypoxic circumstances of poorly vascularized pleomorphic adenomas.
  • [MeSH-major] Adenoma, Pleomorphic / blood supply. Anoxia / physiopathology. Salivary Gland Neoplasms / blood supply. Vascular Endothelial Growth Factor A / genetics. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Alternative Splicing. Antigens, CD31 / metabolism. Biomarkers, Tumor / analysis. Fluorescent Antibody Technique. Humans. Hypoxia-Inducible Factor 1, alpha Subunit. Image Processing, Computer-Assisted. Immunohistochemistry. Proteins / metabolism. RNA, Messenger / analysis. Receptor Protein-Tyrosine Kinases / metabolism. Receptor, Fibroblast Growth Factor, Type 1. Receptors, Fibroblast Growth Factor / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors / metabolism. Vascular Endothelial Growth Factor Receptor-1

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15856293.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Proteins; 0 / RNA, Messenger; 0 / Receptors, Fibroblast Growth Factor; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / FLT1 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


92. Weber T, Cammerer G, Schick C, Solbach C, Hillenbrand A, Barth TF, Henne-Bruns D, Blagieva R, Böhm BO, Reske SN, Luster M: C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism. Horm Metab Res; 2010 Mar;42(3):209-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism.
  • We therefore conducted a study to determine the sensitivity of C-11 methionine positron emission tomography/computed tomography (Met-PET/CT) in localizing parathyroid adenomas in pHPT.
  • Primary HPT was caused by a single gland adenoma in 30 patients, while another 3 patients had multiglandular disease.
  • Met-PET/CT scan correctly located a single gland adenoma in 25 out of 30 (83%) patients with pHPT, among them 2 patients with persistent disease, 7 patients with prior neck surgery, and 8 patients with concomitant thyroid nodules.
  • In 3 patients with multiglandular disease, Met-PET/CT showed only one enlarged parathyroid gland in two individuals and was negative in the third patient.
  • Statistical analysis found a significant correlation between true-positive results and the weight (2.42+/-4.05 g) and diameter (2.0+/-1.18 cm) of parathyroid adenomas while the subgroup with false negative findings had significantly smaller (0.98+/-0.54 cm) and lighter (0.5+/-0.38 g) glands.
  • Sensitivity was 83% for single gland adenomas and 67% for multiglandular disease.
  • Met-PET/CT correctly localized 83% of single gland parathyroid adenomas in patients with pHPT.
  • However, preoperative localization of multiglandular disease due to double adenomas or parathyroid hyperplasia remained difficult.
  • [MeSH-major] Adenoma / radionuclide imaging. Hyperparathyroidism, Primary / radionuclide imaging. Methionine. Parathyroid Neoplasms / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20013649.001).
  • [ISSN] 1439-4286
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 58576-49-1 / carbon-11 methionine; AE28F7PNPL / Methionine
  •  go-up   go-down


93. Ratiu N, Gelbmann C, Rath HR, Herfarth H, Kullmann F, Schölmerich J, Messmann H: Chromoendoscopy with indigo carmine in flexible sigmoidoscopy screening: does it improve the detection of adenomas in the distal colon and rectum? J Gastrointestin Liver Dis; 2007 Jun;16(2):153-6
Hazardous Substances Data Bank. Indigotindisulfonate sodium .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromoendoscopy with indigo carmine in flexible sigmoidoscopy screening: does it improve the detection of adenomas in the distal colon and rectum?
  • BACKGROUND AND AIMS: The aim of our study was to determine whether chromoendoscopy with indigo carmine significantly improves the detection of adenomas in the distal colon and rectum and therefore could become routine in flexible sigmoidoscopy screening.
  • Histologically, 215 (57.7%) were hyperplastic polyps, 27 (7.2%) adenomas and 131 (35.1%) other lesions.
  • With chromoendoscopy, in 17 of the 47 patients (36.2%) 27 adenomas (15 <or= 5 mm and 12 > 5 mm) were detected.
  • Chromoendoscopy significantly improved the detection of adenomas <or= 5 mm (p<0.01).
  • Regarding the detection of adenomas larger than 5 mm, there was no significant difference between conventional sigmoidoscopy and chromoendoscopy.
  • CONCLUSIONS: Chromoendoscopy with indigo carmine allows the detection of significantly more adenomas <or= 5 mm in the distal colon and rectum.
  • [MeSH-major] Adenoma / diagnosis. Colorectal Neoplasms / diagnosis. Coloring Agents. Indigo Carmine. Sigmoidoscopy

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. INDIGO .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592561.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Coloring Agents; D3741U8K7L / Indigo Carmine
  •  go-up   go-down


94. Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Mustafizur Rahman M, Yamada S: Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol; 2008;19(2):82-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form.
  • Pituitary adenomas producing almost exclusively growth hormones (GH) have been ultrastructurally classified into two distinct types: densely granulated somatotroph (DG) adenomas and sparsely granulated (SG) adenomas.
  • Fibrous body (FB), an intracytoplasmic globular aggregation of cytokeratin (CK) filaments, is a hallmark of SG adenomas.
  • However, it has been noted that numerous adenomas contain mixed populations of the two patterns.
  • To clarify clinicopathological characteristics of the adenomas with mixed populations ("intermediate type" adenomas) and to confirm clinicopathological differences between strictly defined DG-type and SG-type adenomas, we performed this study on 104 GH cell adenomas.
  • Having segregated "intermediate-type" adenomas (26 cases), we found significant differences between typical DG-type (47 cases) and SG-type adenomas (31 cases); SG-type adenomas had younger ages (44 vs. 50), higher frequency of macroadenomas (86% vs. 58%), invasiveness (65% vs. 38%), advanced grades (3 or 4) in Knosp's classification (50% vs. 24%), and weaker immunoreaction for GH, beta-TSH, alpha-subunit, E-cadherin, and beta-catenin.
  • Clinicopathological characteristics of "intermediate-type" adenomas were identical to those of DG-type adenomas.
  • These findings confirm that SG-type adenoma is a distinct section of GH cell adenomas with special properties and biological behavior, and suggest that intermediate-phenotype adenomas are enrolled in DG-type adenomas.
  • Special properties and biological behavior of SG-type adenomas may appear after the majority of tumor cells possess a fully developed fibrous body.
  • [MeSH-major] Adenoma / metabolism. Adenoma / pathology. Growth Hormone-Secreting Pituitary Adenoma / metabolism. Growth Hormone-Secreting Pituitary Adenoma / pathology. Keratins / metabolism. Pituitary Neoplasms / metabolism. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18629656.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / beta Catenin; 12629-01-5 / Human Growth Hormone; 68238-35-7 / Keratins; 9002-71-5 / Thyrotropin
  •  go-up   go-down


95. Bajbouj M, von Weyhern C, Becker V, Seidl S, Ott R, Schatke W, Fend F, Schmid RM, Meining A: True adenomas of the cardia: a case series of 3 patients. Digestion; 2008;77(1):65-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] True adenomas of the cardia: a case series of 3 patients.
  • BACKGROUND/AIM: True adenomas of the cardia appear to be extremely rare lesions.
  • We report 3 patients with true adenomas of the cardia.
  • In 2 of the 3 cases Barrett's esophagus with low-grade intraepithelial neoplasia was assumed on the basis of histopathological examination of biopsy specimens taken from the surface of the lesions.
  • In 2 of the 3 cases the final histopathological diagnosis of low-grade adenoma of the cardia could only be established after complete removal of the polypoid masses.
  • CONCLUSIONS: Adenomas of the cardia can be mistaken for dysplasia arising from Barrett's esophagus, if the diagnosis is based on endoscopic biopsies only.
  • [MeSH-major] Adenomatous Polyps / pathology. Cardia / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18349540.001).
  • [ISSN] 1421-9867
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


96. Tanaka A, Takemura-Tsukashita S, Kushima R, Sugihara H, Fujiyama Y, Hattori T: Low-grade gastric adenomas/dysplasias: phenotypic expression, DNA ploidy pattern, and LOH at microsatellites linked to the APC gene. Pathol Res Pract; 2008;204(1):1-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade gastric adenomas/dysplasias: phenotypic expression, DNA ploidy pattern, and LOH at microsatellites linked to the APC gene.
  • The adenoma-adenocarcinoma sequence in the colon is generally accepted.
  • We analyzed the phenotypes, DNA ploidy patterns, and microsatellite regions linked to adenomatous polyposis coli (APC) gene on chromosome 5q of low-grade gastric adenomas/dysplasias, Vienna Category 3, to investigate whether these lesions have the potential to become adenocarcinomas.
  • None of the 15 cases showed coexisting high-grade adenomas/dysplasias or adenocarcinoma.
  • These results suggest that low-grade gastric adenomas/dysplasias, Vienna category 3, seldom progress to gastric adenocarcinomas of the differentiated type.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Chromosomes, Human, Pair 5. Gene Expression Regulation, Neoplastic. Genes, APC. Loss of Heterozygosity. Microsatellite Repeats. Ploidies. Stomach Neoplasms / genetics
  • [MeSH-minor] Cell Differentiation. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Genotype. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Microscopy, Fluorescence. Mucin 5AC. Mucin-2. Mucin-6. Mucins / analysis. Neoplasm Staging. Neprilysin / analysis. Phenotype

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964080.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC6 protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucin-6; 0 / Mucins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


97. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW: Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila); 2008 Jun;1(1):32-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.
  • Preclinical studies of chemoprevention drugs given in combination at low doses show remarkable efficacy in preventing adenomas with little additional toxicities, suggesting a strategy to improve risk to benefit ratios for preventing recurrent adenomas.
  • Three hundred seventy-five patients with history of resected (> or =3 mm) adenomas were randomly assigned to receive oral difluoromethylornithine (DFMO) 500 mg and sulindac 150 mg once daily or matched placebos for 36 months, stratified by use of low-dose aspirin (81 mg) at baseline and clinical site.
  • Colorectal adenoma recurrence was compared among the groups with log-binomial regression.
  • Comparing the outcome in patients receiving placebos to those receiving active intervention, (a) the recurrence of one or more adenomas was 41.1% and 12.3% (risk ratio, 0.30; 95% confidence interval, 0.18-0.49; P < 0.001);.
  • (b) 8.5% had one or more advanced adenomas, compared with 0.7% of patients (risk ratio, 0.085; 95% confidence interval, 0.011-0.65; P < 0.001); and (c) 17 (13.2%) patients had multiple adenomas (>1) at the final colonoscopy, compared with 1 (0.7%; risk ratio, 0.055; 0.0074-0.41; P < 0.001).
  • Recurrent adenomatous polyps can be markedly reduced by a combination of low oral doses of DFMO and sulindac and with few side effects.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Eflornithine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 1999 Dec 13;107(6A):37S-46S; discussion 46S-47S [10628592.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1156-62 [10770980.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1024-8 [10973323.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1155-62 [11097222.001]
  • [Cites] Biometrics. 1999 Sep;55(3):874-82 [11315020.001]
  • [Cites] JAMA. 2001 Aug 22-29;286(8):954-9 [11509060.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):883-90 [12621132.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):781-92 [15510159.001]
  • [Cites] Biometrics. 1979 Sep;35(3):549-56 [497341.001]
  • [Cites] Nature. 1980 Sep 11;287(5778):107-8 [7432445.001]
  • [Cites] J Natl Cancer Inst. 1986 Dec;77(6):1309-13 [3099048.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 3;86(15):1122-30 [8028034.001]
  • [Cites] J Natl Cancer Inst. 1998 Aug 19;90(16):1212-8 [9719082.001]
  • [Cites] Am J Med. 1998 Nov 2;105(5A):3S-9S [9855169.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):101-7 [9887161.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):945-51 [10353725.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1661-9 [15578502.001]
  • [Cites] Recent Results Cancer Res. 2005;166:1-15 [15648179.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Oct;3(10):523 [17019426.001]
  • [Cites] JAMA. 2006 Dec 20;296(23):2815-22 [17179458.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1674-82 [17087947.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Amino Acids. 2007 Aug;33(2):189-95 [17396214.001]
  • [Cites] Biometrics. 2003 Dec;59(4):770-7 [14969454.001]
  • [CommentIn] Cancer Prev Res (Phila). 2008 Jun;1(1):9-11 [19138930.001]
  • (PMID = 18841250.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA059024; United States / NCI NIH HHS / CA / CA72008; United States / NCI NIH HHS / CA / P30 CA023074; None / None / / R01 CA123065-01A2; United States / NCI NIH HHS / CA / CA95060; United States / NCI NIH HHS / CA / P30 CA023074-209010; United States / NCI NIH HHS / CA / CA47396; United States / NCI NIH HHS / CN / N01 CN075019; United States / NCI NIH HHS / CA / R01 CA123065-01A2; None / None / / P30 CA023074-209010; United States / NCI NIH HHS / CA / CA88078; United States / NCI NIH HHS / CN / N01-CN75019; United States / NCI NIH HHS / CA / P50 CA095060; United States / NCI NIH HHS / CA / R01 CA123065; None / None / / P50 CA095060-05; United States / NCI NIH HHS / CA / CA59024; United States / NCI NIH HHS / CA / P01 CA072008; United States / NCI NIH HHS / CA / CA63640; United States / NCI NIH HHS / CA / P30 CA062203; United States / NCI NIH HHS / CA / R01 CA088078; United States / NCI NIH HHS / CA / P50 CA095060-05; United States / NCI NIH HHS / CA / R01 CA063640
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Placebos; 184SNS8VUH / Sulindac; ZQN1G5V6SR / Eflornithine
  • [Other-IDs] NLM/ NIHMS58572; NLM/ PMC2562024
  •  go-up   go-down


98. Pawlikowski M, Pisarek H, Kunert-Radek J, Radek M: Somatostatin receptors in GH-secreting pituitary adenomas--their relationship to the response to octreotide. Endokrynol Pol; 2008 May-Jun;59(3):196-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin receptors in GH-secreting pituitary adenomas--their relationship to the response to octreotide.
  • Twenty pituitary adenomas, surgically removed from patients suffering from acromegaly, were studied.
  • All the adenomas examined expressed rsst2A (20/20) and rsst5 (12/12) receptor proteins.
  • The mixed (GH/PRL) adenomas showed a tendency to a higher expression of rsst2A + + rsst2B and a greater response to octreotide administration.
  • Both isoforms of rsst2 mediate the same biological response (inhibition of GH secretion) in GH-secreting and GH/PRL-secreting adenomas.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / metabolism. Growth Hormone-Secreting Pituitary Adenoma / drug therapy. Growth Hormone-Secreting Pituitary Adenoma / metabolism. Octreotide / therapeutic use. Receptors, Somatostatin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18615392.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Somatostatin; 9002-72-6 / Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


99. Lim KH, Ward SC, Roayaie S, Cohen E, Schwartz M, Fiel MI, Thung SN: Multiple inflammatory and serum amyloid A positive telangiectatic hepatic adenomas with glycogenated nuclei arising in a background of nonalcoholic steatohepatitis. Semin Liver Dis; 2008 Nov;28(4):434-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple inflammatory and serum amyloid A positive telangiectatic hepatic adenomas with glycogenated nuclei arising in a background of nonalcoholic steatohepatitis.
  • The authors describe multiple telangiectatic or inflammatory adenomas in a 53-year-old woman with steatohepatitis who presented with acute right upper quadrant abdominal pain.
  • Magnetic resonance imaging revealed 6 lesions consistent with multiple hepatic adenomas, 2 of which showed hemorrhage.
  • All nodules contained portal-like structures and ductular reaction, features seen in focal nodular hyperplasia, as well as significant inflammation, telangiectatic sinusoids and immunoreactivity for serum amyloid A, placing them according to a recently described classification systems as telangiectatic or inflammatory adenomas.
  • [MeSH-major] Adenoma / pathology. Fatty Liver / pathology. Liver Neoplasms / pathology. Serum Amyloid A Protein / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956299.001).
  • [ISSN] 0272-8087
  • [Journal-full-title] Seminars in liver disease
  • [ISO-abbreviation] Semin. Liver Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Serum Amyloid A Protein
  •  go-up   go-down


100. Simeonov RS, Simeonova GP: Use of quantitative analysis as a method for differentiation between canine cutaneous apocrine adenomas and apocrine carcinomas on cytological smears. J Vet Med A Physiol Pathol Clin Med; 2007 Nov;54(9):542-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of quantitative analysis as a method for differentiation between canine cutaneous apocrine adenomas and apocrine carcinomas on cytological smears.
  • Eight canine cutaneous adenomas and eight canine cutaneous carcinomas were analysed by computer-assisted nuclear morphometry in Hemacolor-stained cytological specimens.
  • The results indicated an increase in the mean values of investigated parameters from canine cutaneous apocrine adenomas (MNA, 75.65+/-2.22; MNP, 31.05+/-0.55; MND, 9.62+/-0.14; NR, 1.10+/-0.009) to canine cutaneous apocrine carcinomas (MNA, 88.78+/-11.29; MNP, 34.38+/-2.43; MND, 10.43+/-0.76; NR, 1.21+/-0.07).
  • The statistical analysis revealed statistically significant differences between benign and malignant neoplastic cells (P<0.01).
  • The results indicated that the computerized morphometry could be used as an effective auxiliary tool for differential diagnosis between canine cutaneous adenomas and carcinomas on cytological smears.
  • [MeSH-major] Adenoma / veterinary. Apocrine Glands / cytology. Carcinoma / veterinary. Cell Nucleus / pathology. Dog Diseases / pathology. Sweat Gland Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931233.001).
  • [ISSN] 0931-184X
  • [Journal-full-title] Journal of veterinary medicine. A, Physiology, pathology, clinical medicine
  • [ISO-abbreviation] J Vet Med A Physiol Pathol Clin Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement